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RUNX3 is a transcription factor that is ubiquitously expressed in different tissues and has 
been shown to have diverse functions in many developmental procedures. Recently it has also 
been acknowledged that RUNX3 is involved as a tumor suppressor in many distinct cancers in 
different tissues. In this thesis, we will examine the regulation of this tumor suppressor in gastric 
cancer and breast cancer.  
Chronic infection with cagA-positive Helicobacter pylori is the strongest risk factor for 
the development of gastric adenocarcinoma. The cagA gene product CagA is injected into gastric 
epithelial cells and disturbs cellular functions by physically interacting with and deregulating a 
variety of cellular signaling molecules. RUNX3 is expressed gastric epithelial tissues, and is 
frequently inactivated in gastric cancer. In the first part of the thesis, we showed that H. pylori 
infection inactivates the gastric tumor suppressor RUNX3 in a CagA-dependent manner. CagA 
directly associates with RUNX3 through a specific recognition of the PY motif of RUNX3 by a 
WW domain of CagA. Deletion of the WW domains of CagA or mutation of the PY motif in 
RUNX3 abolishes the ability of CagA to induce the ubiquitination and degradation of RUNX3, 
thereby extinguishing its ability to inhibit the transcriptional activation of RUNX3. This study 
identify RUNX3 as a novel cellular target of H. pylori CagA and also reveal a mechanism by 
which CagA functions as an oncoprotein by blocking the activity of gastric tumor suppressor 
RUNX3. 
RUNX3 has also been known to be inactivated in breast cancer through dual mechanism 
of cytoplasmic mislocalization as well as promoter hypermethylation. Recent studies in our lab 
have shown that RUNX3 knockout mice have an approximate 20% increased chance of 
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developing breast cancer compared to WT mice. At the same time, MCF7 cells expressing 
RUNX3 resulted in smaller tumor growth in a tumorigenicity assay compared to MCF7 cells 
expressing a control vector, further affirming RUNX3’s importance as a tumor suppressor in 
breast cancer. Pin1 is an isomerase that is over-expressed in human breast cancer. Pin1 
specifically isomerizes only the Ser/Thr-Pro bonds in certain proteins, which allows it to act as a 
molecular switch controlling protein functions. In the second part of this thesis, we discuss the 
findings that Pin1 interacts specifically with tumor suppressor protein RUNX3 through 4 
separate phosphorylated Ser/Thr-Pro motifs on the RUNX3 protein. Through this interaction 
with Pin1, the ubiquitination of RUNX3 is markedly enhanced, resulting in decreased protein 
stability. RUNX3 is therefore targeted to the 26S proteasome for degradation in the presence of 
Pin1. Our data shows a novel pathway through which tumor suppressor protein RUNX3 can be 
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Chapter 1:  










1.1 Brief Introduction to the RUNX family. 
Over the years, the RUNX gene family which encodes for Runt domain containing 
transcription factors has been attracting a broad interest group because of their involvement in 
cell lineage determination during development and various forms of cancers. RUNX1 is 
associated with hematopoeisis, RUNX2 is important in bone formation. RUNX3 is ubiquitously 
expressed in many tissues with diverse biological functions, of which the most widely studied is 
its role as a tumor suppressor.  
 
The transcription factors encoded by the RUNX mammalian family was discovered by 
virologists who made used of DNA and RNA tumor viruses to study cellular growth and 
differentiation processes. DNA and RNA tumor viruses have been involved in many landmark 
studies that defined numerous basic processes of carcinogenesis. p53, for example, was found to 
be bound to the middle T antigen of a DNA virus, simian virus 40 [1]. One of the methods of 
research capitalized on the usage of embryonal carcinoma (EC) cells, which have properties 
identical to early embryos [2]. Under specific conditions, EC cells that are introduced into 
blastocysts can differentiate into normal tissues in chimeric mice [3, 4]. Virologists found that 
EC cell lines, such as F9 and PCC4, are resistant to infection by several viruses including 
polyomavirus (Py) until cells are induced to differentiate. [5, 6]. Py contains an enhancer region 
that determines the differentiation of stage-specific viral infections, and vigorous analysis of the 
Py enhancer led to the isolation of a critical cellular transcription factor [7, 8], Py enhancer 
binding protein 2 (PEBP2), later known as a RUNX protein [9]. The PEBP2 was identified as a 
developmental regulator that was only expressed when EC cells undergo differentiation.  
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Besides DNA and RNA tumor viruses, murine retroviruses were also found to induce 
tumors in various tissues. Oncogenes and proto-oncogenes were identified by their transduction 
into viral genomes or by viral integration into regulatory regions of cellular genes. RUNX 
protein was identified as a core-binding factor (CBF) that modified the regulatory elements of 
retrovirus enhancers, and affected the oncogenic potential of the virus [10-12]. Further studies 
confirmed that PEBP2 and CBP are identical proteins. Subsequently, two other genes that had 
been identified by other groups of researchers were also found to be related to PEBP2/CBF, 
eventually forming the RUNX family of proteins [13-16].  
 
The functions of RUNX gene family were largely obtained through studies of various 
RUNX knockout mice. Embryonic RUNX1 mice of 12.5-13.5 days old had no or very few 
definitive hematopoietic progenitors in their fetal livers or yolk sac [17-19].  Further studies 
showed that RUNX1 is vital in the generation of hematopoietic stem cells (HSCs) during 
embryogenesis [20-22]. HSCs are generated from several distinct embryonic sites, examples of 
which include the para-aortic splanchnopleura (PAS) and the aorta-gonad-mesonephros (AGM) 
which is formed in later developmental stages. RUNX1 is expressed in all of these hematogenic 
endothelial cells [23] and lack of RUNX1 in these endothelial cells renders them incapable of 
producing HSCs. Hence, presenting RUNX1 as an early marker of endothelial and mesenchymal 
cells in the sites of HSC emergence.  
 
In the case of adult hematopoiesis, conditional knock out of RUNX1 in adult mice did not 
result in the abolishment of HSC function.  However, the mice did show defects in platelet 
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formation and megakryocyte differentiation [24, 25], which are disorders with predisposition to 
acute myelogenous leukemia (AML) [26]. There was also a decreased contribution to peripheral 
T-cell populations in Runx1
-/-
 mice, β chain rearrangements and /or β-selection [27]. RUNX1 
knockout mice eventually developed myeloproliferative disease and T-cell lymophoma. 
RUNX1’s role as a global regulator in hematopoiesis across multiple stages and lineages is 
further evident from the fact that is it one of the most frequently mutated genes in human 
leukemias [28, 29].  
 
Likewise, through knockout mice experiments, RUNX2 was shown to be a key player in 
osteoblast proliferation and differentiation and is obligatory for regulation of skeletal genes, 
hypertrophic chodrocytes as well as endochondral and intramembraneous bone formation and 
skeletal development [30-32]. RUNX2 knockout mice suffocated to death soon after birth due to 
missing rib cage formation, a result of systemic lack of ossification. Supporting the data from 
Runx2
-/-
 mice, mutations in RUNX2 were also reported in the human congenital skeletal disorder 
cleidocranial dysplasia (CCD) [31, 32]. A better understanding of RUNX2 and its function will 
provide further insights into bone biology and novel therapeutics.  
 
RUNX3 is expressed in a wider range of tissues than RUNX1 and RUNX2, the knockout 
phenotype of RUNX3 is observed in several different tissues. Firstly, the gastric mucosa of 
Runx3
-/-
 mice was found to exhibit hyperplasia as a result of increased cell proliferation and 
suppressed apoptosis in epithelial cells. Furthermore the cells were immune to growth inhibitory 
and apoptosis inducing effects of Transformation Growth Factor β (TGF-β), suggesting that 
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RUNX3 is a major growth regulator of gastric epithelial cells and is a tumor suppressor in gastric 
cancer. Subsequently over the next few years, RUNX3 was also discovered to be a putative 
tumor suppressor in many solid tumor types including breast cancer [33, 34], lung cancer [35], 
and colorectal cancer [36]. The tumor suppressor activities of RUNX3 in gastric cancer and 
breast cancer will be further discussed in the following chapters.  
 
RUNX3 is also found to regulate the development of dorsal root ganglion (DRG) neurons 
and is required for the axon path finding of proprioceptive neuron in the spinal cord. It was 
reported that Runx3
-/-
 mice displayed severe failure in motor coordination, and few DRG neurons 
synthesized parvalbumin, the proprioceptive neuronal marker [37, 38]. Furthermore, 
proprioceptive afferent axons failed to project to their targets in the spinal cord and muscles. 
DRG neurons project axons to central and peripheral targets according to the sensory modality, 
RUNX3 was found to be expressed in some subpopulations of DRG neutrons suggesting that the 
protein may have a function in regulating the paths of specific axons. These data suggest the 







 mice were found to have a defect in T cell 
development. These mice displayed reduced numbers of CD8
+
 T cells in the thymus and in the 
circulating T-cell population [39]. On the other hand, there was an increased expression of CD4 
in the peripheral CD8
+
 cells [40]. RUNX3 deficient cytotoxic T cells had defective responses to 
antigens while the helper cells functioned normally. Briefly, T lymphocytes differentiates 
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through the following stages: Hematopoietic precursors lacking CD4 and CD8 receptors progress 




), and are then selected to become either a CD4
+
 
helper cell or CD8
+
 cytotoxic T cell through the silencing of either CD8 or CD4 expression 
respectively. Two consensus RUNX binding site have been found in the regulatory element 
required for CD4 silencing during T-cell development, and different RUNX family members are 
required for unique functions at different stages [27]. RUNX1 binds to both sites and is required 




 thymocytes, while RUNX3 is important in CD4 silencing 














1.2 RUNX3, a Transcription Factor, and its Anti-Tumor Properties 
After purification of the RUNX family transcription factors from the Py enhancer, 
biochemical methods revealed that the three transcription factors are heterodimers: a DNA 
binding α-subunit, and a common non-DNA binding β-subunit known as PEBP2β/CBF-β [9, 13], 
which enhances the DNA binding property of the α-subunits. The α-subunits of the three 
members share a central Runt domain, which is well conserved and recognizes a specific DNA 
sequence. The Runt domain is highly conserved from Drosophila melanogaster segmentation 
runt gene which is found to be important for the developmental regulation of early Drosophila 
embryos [15, 41, 42]. The RUNX genes are able to encode a number of isoforms due to the 
presence of two alternative promoters, distal promoter P1 and proximal promoter P2 [43]. The 
functional significance of this complex organization and coding potential is still unclear. The 
most common isoform of RUNX proteins is the type 1 isoform that contains the pentapetide 
MRIPV at its N-terminus, we will be using this isoform for our study of RUNX3 in this thesis. 
 
One of the most extensively studied functional properties of RUNX3 is its involvement in 
the TGF-β signaling pathway. TGF-β is a growth factor that controls proliferation, cellular 
differentiation and numerous other diverse biological pathways. During TGF-β signaling, TGF-β 
or bone morphogenetic protein (BMP) binds to their respective cognate receptors, resulting in the 
activation of the receptors as serine kinases. These serine kinases then phosphorylate Smads, 
which are signal transducers in the TGF-β signaling pathway. Smad2 and Smad3 are activated by 
TGF-β, while Smad1, 5 and 8 are activated by BMP. The Smads that can be activated by 
receptors are known as R-Smads, they associated with a common Smad4, known as Co-Smad 
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and translocate into the nucleus. The R-Smads and Co-Smad complexes then interact with 
respective transcription factors to regulate the transcription of target genes [44]. RUNX3 is 
known to interact with Smad3 and Smad1 through the MH2 domains in the C-terminal conserved 
regions of the Smad proteins while Smads are believed to interact with RUNX3 at at least 2 
regions, one at the C-terminal transcription activation domain, and the other within the Runt 
domain in the middle of the protein [45]. 
 
Figure 1.1 Structure of human RUNX family of proteins and their phosphorylation sites, adapted 
from [46]. Conserved regions in RUNX proteins are indicated by dotted lines. AD stands for 
transactivation domain of RUNX1 (Ito, 1999), AD3 for transactivation domain of RUNX2 
(Thirunayukkarasu 1998), ID for inhibitory domain, Q for glutamine tract, A for alanine tract 
and lastly, PST region for proline serine and threonine-rich region.  
 
The synergistic relation between RUNX3 activity and TGF-β signaling was observed 
when the gastric mucosa of RUNX3 knockout mice was less sensitive to TGF-β induced cell 
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cycle arrest and apoptosis [47]. This observation together with the ability of RUNX3 to target 
Smad regulators to distinct nuclear foci on stimulation by TGF-β further strengthens the case for 
RUNX3 as a regulator of the TGF-β signaling pathway [48]. Given that RUNX3 is an integral 
part of the TGF-β signaling pathway, these observations fit nicely with earlier studies which 
found that TGF-β signal transduction pathway are interrupted in many types of cancers, 
including those of the gastrointestinal tract. It is therefore possible to extrapolate that RUNX3 
might also function as a tumor suppressor in other types of cancers where mutations or deletions 
are often found in the TGF-β receptors or other components of the signaling pathway [49, 50].  
 





 [51-54]. It was observed in a study in 2006 that RUNX3 inhibited gastric 
epithelial cell growth by inducing p21 gene expression in response to TGF-β1. The study showed 
that increase in exogenous expression of RUNX3 increased endogenous p21 expression upon 
TGF-β1 stimulation. Moreover, siRNA suppression of RUNX3 expression decreased TGF-β 
induced p21 expression. In mouse and human epithelial sections, RUNX3 expression coincided 
with p21 expression. The presence of five RUNX3 binding sites on the p21 promoter also further 
indicated that p21 is a direct target of RUNX3 [55]. Upon TGF-β activation, R-Smads are 
activated they bind with RUNX3 and cooperatively stimulate the activation of p21 promoter to 
induce TGF-β-mediated cell cycle arrest. This discovery provides a first insight into RUNX3’s 
role in the TGF-β signaling pathway in the gastric epithelial, suggesting that part of RUNX3’s 
tumor suppressor activity is to influence the cell cycle machinery and induce cell cycle arrest, 
and thereby inhibiting cell growth. 
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Another gene that has been found to be a direct downstream target of RUNX3 is Bim, a 
pro-apoptotic gene. Bim was found to be one of the proteins involved in the activation of TGF-β 
induced apoptosis, and was up-regulated by RUNX3 in response to TGF-β stimulation [56]. Data 
from the report showed that Bim pathway is the major pathway that is operating in TGF-β 
mediated apoptosis by RUNX3 in vivo and in vitro. Therefore suggesting that besides regulating 
cell cycle arrest, another of RUNX3’s tumor suppressor activity would be to mediate apoptosis 
through Bim. Subsequently, claudin-1, an integral membrane protein, important in maintaining 
the integrity of cell-cell adhesion was also found to be a direct transcriptional target of RUNX3. 
RUNX3 cooperates with TGF-β to regulate claudin-1 transcription. RUNX3-/- derived gastric 
epithelial cells were attached weakly to each other as compared to RUNX3
+/+
 cells, and had 
reduced levels of claudin-1 [57]. Claudin-1 is also believed to be a gastric tumor suppressor; it 
inhibits proliferation in gastric cancer cells and is down-regulated during epithelial-mesenchymal 
transition (EMT). These findings present another mechanism of RUNX3’s anti-tumor activity, 





Figure 1.2 RUNX3 cooperates with SMAD3 and SMAD4 to activate TGF-β-dependent growth 
inhibition and apoptosis by induction of p21 and Bim respectively; RUNX3 induces Claudin-
1 (Cldn-1) expression, possibly to antagonize epithelial-mesenchymal transition process.  
 
While regulating TGF-β signaling, RUNX3 is also found to be regulated by components 
of the TGF-β signaling pathway. TGF-β was observed to stimulate p300-dependent RUNX3 
acetylation, and this acetylation counters Smurf-mediated ubiquitination and degradation of 
RUNX3 [58, 59]. Increase in RUNX3 acetylation increases its transcriptional activity. Since 
acetylation and ubiquitination both target lysine residues, it is probable that the acetylation of 
RUNX3 competes with its ubiquitination. Furthermore, mutations of the lysine residues in 
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RUNX3 abolished the transactivation activity of RUNX3 despite markedly increasing its 
stability suggesting that TGF-β mediated acetylation of RUNX3 is not only important in 









Figure 1.3 Hypothetical model for the acetylation, deacetylation and ubiquitination of RUNX3, 
from [46]. The cellular levels of RUNX amounts and activity are controlled by a dynamic 
equilibrium of RUNX acetylation and deacetylation.  Under normal circumstances, low levels of 
RUNX3 activity will be maintained by decreased acetylation of RUNX3 through deacetylase 
activity, such that the RUNX3 protein is exposed to ubiquitin ligase and targeted for degradation. 
When a signal the likes of TGF-β or BMP is present, RUNX3 acetylation is increased by 
increased p300 activity, hence inhibiting ubiquitination and degradation of RUNX3.  
 
Besides being an integral part of the TGF-β signaling pathway, RUNX3 is also found to 
antagonize Wnt signaling activity and down-regulate transcription of Wnt target genes such as c-
Myc and cyclinD1 in the epithelial cells of small and large intestines. Further studies showed that 
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RUNX3 exists in a complex with key Wnt effectors: TCF4 and β-catenin, and the resulting 
complex shows reduced DNA binding activity, and decrease transcriptional activation of Wnt 
target genes. Furthermore, this antagonism against aberrant Wnt signaling is APC independent, 
indicating that RUNX3 is a gatekeeper of Wnt signaling on its own [36]. RUNX3’s involvement 
in both the TGF-β pathway and Wnt signaling may well provide an opportunity to orchestrate 
tumor suppressor activity through crosstalk between the two pathways. It is also interesting to 
note that both Wnt and TGF-β signaling pathways are also involved in EMT during embryonic 
development [60]. However, it is not clear if RUNX3 affects the ability of these two pathways to 
in EMT.  
 
RUNX3 is also believed to have putative functions in other cancer signaling pathways. 
The interaction between RUNX3 and yes-associated protein (YAP), a transcription co-activator, 
is thought to enhance target promoter activation of RUNX3 [61]. RUNX3 also physically binds 
to Forkhead box O3a (FOXO3a) tumor suppressor protein at the promoter of Bim, enhancing 
transcription of Bim and subsequently increase cellular apoptosis [62]. It is entirely possible that 
RUNX3 is involved in other FOXO3a-related activities including regulation of intestinal 
inflammation [63], activation of ATM during DNA damage [64] and oxidative stress response 
[65]. DNA damage has known to promote carcinogenesis through genetic alternations of 
components involved in signaling pathway, cell cycle regulation, repair and apoptosis processes. 
Incidentally, reports have also linked RUNX3 with various DNA repair machineries; one 
example is RUNX3’s interaction with DNA repair protein Ku70, a component of the major 
repair mechanism for double-stranded DNA breaks and non-homologous end-joining repair [66]. 
Finally, RUNX3 is also believed to be a mediator of cellular senescence. Oncogene-induced 
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senescence is an important method of tumor suppression, and RUNX3 is believed to mediate this 
mode of growth arrest through the induction of p14
ARF
 in a p53 dependent manner [67, 68].  All 
these findings indicate the multi-functionalities of RUNX3 in different types of tumors. The anti-
tumor mechanism of RUNX3 in each type of tumor has to be better studies in order to gain 















1.3: Knockout Phenotype of RUNX3: Gastric Cancer Tumor Suppressor 
The identification of RUNX3 as a candidate tumor suppressor in gastric cancer was an 
important discovery in the field of gastric carcinoma. Gastric cancer is the fourth most common 
type of cancer and the second leading cause of cancer related death worldwide [69-71]. Risk 
factors leading to gastric carcinoma include diet, Helicobactor pylori (H. pylori) infection and 
genetic alterations [72, 73]. Many genetic mutations associated with gastric cancer have been 
described including loss of expressing of genes like TGF-β receptor [74] and p53 [75, 76] or 
over expression of erbB-2 [77] and c-met [78]. Loss of multiple chromosomal loci has also been 
linked to gastric cancer [79-81], but all of the above were only presented in limited cases where 
the significance of such genetic alternations was unknown. Until the discovery of RUNX3 as a 
tumor suppressor in gastric cancer, the underlying mechanism of gastric carcinogenesis was 
poorly understood.  
 
In 2002, Li et at. described RUNX3 as being expressed in glandular stomach, with the 
strongest expression in chief cells and surface epithelial cells and to a lesser extend in parietal 
cells in the normal human adult gastric. RUNX3 null mouse gastric mucosa demonstrated signs 
of hyperplasia due to increased proliferation and resistance to TGF-β-induced growth inhibitory 
effect or apoptosis in the epithelial cells. Examination of 46 surgically resected gastric cancer 
specimens and cell lines showed that approximately 60% of the patient samples did not express 
RUNX3 due to hemizygous deletion of the gene or hypermethylation of its promoter region. The 
incidence of RUNX3 silencing appeared to happen at an early stage as well as during 
progression, from 40% of early stages of cancer to almost 90% of stage IV cancer. Data 
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indicated that loss of RUNX3 is causally linked to the genesis and progression of gastric cancer. 
A rare missense loss-of-function mutation in the Runt domain of RUNX3 (R122C) was also 
identified from a cancer patient. This single amino acid mutation resulted in complete 
abolishment of RUNX3’s DNA binding ability and negated the tumor suppressor activity of 





 mice with a p53 
-/-





cell line was tumorigenic in nude mice, confirming RUNX3 as gastric tumor suppressor  [47].  
 
In a subsequent study by Ito et al . in 2005, 97 gastric cancer cases were tested and it was 
discovered that in 44% of the cases, RUNX3 was not expressed, consistent with the findings 
from 2002. In the remaining 56% of samples where RUNX3 was expressed, only 18% showed 
nuclear localization of RUNX3, while 38% showed primarily, or exclusively retention of 
RUNX3 in the cytoplasm as an inactive form [82]. Transcription factors require translocation 
into the nucleus in order to carry out transactivation of target genes, and often the nuclear 
envelope functions as a line of regulation to prevent transcription factors from gaining access to 
target genes. Therefore proper sub-nuclear targeting of transcription factors is an important step 
in signaling transduction pathways. Transcription factors that are retained in the cytoplasm are 
believed to be in a basal and inactive state, likewise with the RUNX3 protein seen in 38% of the 
gastric cancer cases studied in 2005. With this report, it can be concluded that RUNX3 is 
inactivated in almost 90% of gastric cancers through hemizygous deletion of the gene, 
hypermethylation of the Runx3 promoter or mis-localization of the RUNX3 protein to the 
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cytoplasm [82], further emphasizing on RUNX3’s role as a candidate tumor suppressor in gastric 
cancer.  
 
Interestingly, the human Runx3 gene is on the short arm of human chromosome 1 at 
location 1p36 [83], a location that is thought to carry important tumor suppressor(s) in many 
types of cancers including gastric cancer, hepatocellular carcinoma, colon carcinoma, pancreatic 
cancer and neuroblastoma [84]. Indeed, as previously mentioned, there have been increasing 
reports of RUNX3 being possibly involved as a tumor suppressor in many other types of cancer 
including, but not limited to lung cancer [35], colorectal cancer [36], liver cancer [85] and breast 
cancer [33, 34]. The role of RUNX3 in breast cancer will be further discussed in the subsequent 
part of this chapter.  
 
It is also important to note that RUNX3 that had been silenced through hypermethylation 
of its promoter can be reactivated by the combination of 5’-azacytidine and Trichostatin A 
(histone deacetylase inhibitors) treatment [47]. Also, although on average, 30% of gastric cancer 
cases show hemizygous deletions of RUNX3, mutations or small deletions in the remaining 
allele were very rare. Likewise for alleles silenced by hypermethylation of the gene promoter, 
mutations of the alleles were rare, implying that reactivation of the RUNX3 gene would possibly 
reactivating a fully functional protein. Also, exogenous expression of RUNX3 in a cell line 
where RUNX3 had been silenced was able to reverse the tumorigenicity of that cell line in nude 
mice [47]. These data suggest that need for more detailed studies of the RUNX3 and its tumor 
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suppressor activity in hope that these studies would one day be useful in countering tumor 

















1.4 RUNX3, a Possible Tumor Suppressor in Breast Cancer? 
Breast cancer is the most common type of cancer amongst woman in developed countries, 
including the United States. With a mortality of approximately 20%, breast cancer is the second 
deathliest form of cancer after lung cancer [86]. Carcinogenesis of breast cancer is a multistep 
process that begins with aberrant growth of mammary epithelial cells, and ending with formation 
of invasive tumors. There are two types of breast cancer: cancers originating from milk ducts are 
known as ductal carcinomas, and cancers originating from breast lobules (that supply the ducts 
with milk) are known as lobular carcinomas. The initiation of breast cancer is due to many 
factors, including age, race and diet. However, genetic alterations such as mutations in BRCA1 
and BRCA2 remain a strong link to many breast cancer cases [87]. Therefore, identification of 
the genetic changes involved in the multistep of breast cancer is important for early detection and 
prevention.  
 
There has been strong evidence suggesting that mutations in the TGF-β signaling 
pathway might be one of these genetic aberrations that result in mammary tumor formation. 
Researchers noticed that majority of breast cancer cell lines did not respond to TGF-β-mediated 
cell cycle arrest although the TGF-β signaling cascade involving Smads was active in these cells 
[88] . Some other factor is thus suspected to be hindering TGF-β induced cell cycle arrest or 
apoptosis in breast cancer cells. RUNX3’s involvement in the TGF-β-mediated tumor suppressor 
pathway, and also its TGF-β-dependent transactivation of p21 and Bim genes in gastric cancer 
[55, 56] led researchers to suspect its likelihood as a candidate in the inactivation of TGF-β 
signaling pathway in breast cancer.  
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In fact, study by Lau et al .  in 2006 discovered that 12 out of 19 breast cancer cells lines 
displayed low RUNX3 mRNA and protein expression due to promoter hypermethylation of the 
RUNX3 gene. They further studied RUNX3 expression in primary breast cancer specimens from 
patients in Singapore and found that 9 out of 44 specimens showed undetectable levels of 
RUNX3 through immunohistostaining of the RUNX3 protein. In the remaining 35 specimens 
that showed weak staining for RUNX3, the protein was localized to the cytoplasm. Using a nude 
mice tumorigenicity assay, the researchers showed that only nude mice injected with MDA-MB-
231 stably expressing RUNX3 developed tumors while none of the mice injected with MDA-
MB-231 cells expressing a control vector developed tumors [34]. 
 
 These results were further confirmed by a separate study in China in 2008, where they 
reported that 50% of breast cancer specimens examined did not express RUNX3 do to 
hypermethylation of the gene promoter. They also observed that the survive rate of patients was 
linked to RUNX3 expression. Breast cancer patients with positive RUNX3 expression have an 
84% 5-year survival rate as compared to 54% in patients with negative expression of RUNX3 
[89].  
 
The above data suggest a possible tumor suppressor role for RUNX3 in breast cancer, but 
it is not until a study published by Huang et al. in our lab with our collaborators that documented 
a mechanism by which RUNX3 carries out its tumor suppressor activity. In the report, we 
demonstrated that about one fifth of the Runx3
+/-
 mice developed spontaneous ductal 
adenocarcinomas due to increase cell proliferation, compared to WT Runx3
+/+
 mice, none of 
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which had tumor growths in their mammary glands. Immunohistochemistry of the Runx3
+/- 
tumors showed marked decrease in the RUNX3 expression compared to WT mammary tissues, 
supporting the notion that RUNX3 is a tumor suppressor in breast cancer. It was interesting to 
note that estrogen receptor-α expression was markedly increased in Runx3+/- tumors as compared 
to WT tissues. Further studies using series of assays including proliferation assay, soft agar assay 
and nude mice tumorigenicity assay show that RUNX3 inhibit estrogen-dependent proliferation 
in a breast cancer cell line, MCF-7 cells [33].  
 
The negative correlation between RUNX3 and ERα observed in Runx3+/- mice described 
above was further proven in a cohort of 80 human breast ductal carcinoma samples. We observed 
that 70% of the samples with low RUNX3 expression had high expression of ERα while 
conversely, 65% of samples with high RUNX3 expression displayed low ERα expression. 
Subsequent investigation showed that RUNX3 induced proteasome degradation of ERα in a 
ligand independent manner resulting in the inactivation of ERα transcriptional activity [33].  
 
Estrogen plays a critical role in mammary gland development [90], and its action is 
mediated through estrogen receptor α and β. ERα is able to function as a transcription factor 
regulating genes involving in cell cycle and apoptosis, resulting in cell proliferation and 
suppression of apoptosis [91]. ERα is over-expressed in 75% of breast cancers [91], and aberrant 
ERα expression and subsequent abnormal estrogen signaling is associated with initiation and 
progression of breast cancer [92]. Therefore, tight control of the level of ERα is important for 
normal mammary tissues development. It is possible that RUNX3 might recruit an E3 ubiquitin 
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ligase or function as an E3 ubiquitin ligase for the ubiquitination and degradation of ERα, acting 
as a gatekeeper for the level of ERα in the mammary tissues.  
 
All of the above data points towards RUNX3 as a tumor suppressor in breast cancer. 
Huang et al . defined a mechanism for the tumor suppressor of RUNX3 in ERα-positive breast 
cancers. However, it should also be noted that since RUNX3 expression is also down-regulated 
in some ERα negative cells like MDA-MB-231, and that RUNX3 did reduce the invasiveness 
and tumor forming potential of those cells like previously described [34], the mechanism tumor 
suppressor activity of RUNX3 in ERα negative cancer is possibly different from ERα positive 
cancer.  
 
As RUNX3 is frequently inactivated in gastric and breast tumors, studying the regulation 
of RUNX3 and restoring RUNX3 expression in those tissue types presents an attractive new 













Chapter 2: Helicobacter pylori CagA 
targets gastric tumor suppressor RUNX3 












2.1 Introduction: H. Pylori CagA and Gastric Cancer 
Infection with H. pylori is the strongest risk factor for gastric carcinoma [73]. H. pylori is 
a micro-aerophilic spiral-shaped bacterium which colonizes at least half of the world’s 
population. It is subdivided into cytotoxin-associated gene A (cagA)-positive and cagA-negative 
strains. CagA-positive strains are much more potent in causing gastric mucosal damage [93, 94]. 
The CagA gene is a 120-145 kDa protein located at one end of the cag pathogenicity island 
(PAI), which is a roughly 40 Kb segment of the H. pylori genome that is considered to have been 
acquired by a process of horizontal transfer from an unknown organism. Genes located in this 
region mediate the pathogenicity of this bacterium [95-99]. One example is the type IV secretion 
system which delivers the cagA-encoded CagA protein into host cells [100]. 
 
Recent research has found H. pylori CagA to be a bacterial oncoprotein that acts in 
mammals. Transgenic expression of CagA alone in mice was able to induce abnormal 
proliferation of gastric epithelial cells and hematopoietic cells. CagA transgenic mice developed 
gastrointestinal carcinomas and leukemia, highlighting the oncogenic potential of CagA in 
gastric cancer [101].  While it is clear that CagA is probably sufficient to induce gastric cancer, 
the detailed mechanism is still unclear. Several mechanisms for CagA-dependent induction of 
gastrointestinal carcinomas have been proposed.  For example, when CagA is delivered into the 
gastric epithelial cells, it causes the aberrant activation of SHP-2 tyrosine phosphatase which is a 
bona fide oncoprotein in human malignancies [72, 102]. Phosphorylation-independent 
interaction of CagA with PAR1, which inhibits PAR1 kinase activity and thereby causes 
junctional and polarity defects in gastric epithelial cells, is also suspected to be involved in the 




Figure 2.1 Adapted from [104]. Figure shows the sequential interaction of CagA with PAR1 and 
SHP-2. CM stands for CagA-multimerization sequence, which is important for the dimerization 
of CagA.  
 
Another possibility is the relationship between CagA and the Wnt/-catenin signaling 
pathway. The Wnt/-catenin signaling pathway is crucially involved in colorectal carcinogenesis 
[105]. CagA is known to destabilize E-cadherin/-catenin complex at the membrane, causing 
nuclear translocalization of -catenin and subsequently the activation of Wnt/-catenin signaling 
[106, 107]. CagA-deregulated -catenin transactivates several genes which govern intestinal 
differentiation and thereby induces intestine-specific marker mucin 2 in gastric epithelial cells. 
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This indicates that perturbation of the E-cadherin/-catenin by CagA plays an important role in 
the development of intestinal metaplasia, a premalignant transdifferentiation of gastric epithelial 
cells from which intestinal-type gastric adenocarcinoma arises. However, despite all of the above 
hypotheses, the exact mechanism of CagA-induced tumorigenesis remains obscure.  
 
Figure 2.2 Adapted from [104]. Illustration of CagA interacting with E-cadherin at the gastric 
epithelial membrane, leading to the destabilization of E-cadherin/β-catenin complex, eliciting 
deregulated Wnt signaling.  
 
In addition, emerging evidence discussed in chapter 1.3 that suggests that RUNX3 is a 
tumor suppressor whose inactivation is involved in the initiation and progression of gastric 




Here in this chapter, we demonstrate that virulence factor CagA of H. pylori specifically 
associates with RUNX3 and down-regulates its expression in gastric epithelial cells. CagA 
targets RUNX3 for ubiquitination and proteasome-mediated degradation. The identification of 
RUNX3 as a novel cellular target of CagA will help better understand the role of CagA as an 
















2.2 Materials and methods 
Cell culture 
Human AGS gastric epithelial cells, HEK293T and COS7 cells were obtained from ATCC 
(Manassas, VA, USA) and maintained in Dulbecco’s Modified Eagle Medium (DMEM) (Sigma, 
St Louis, MO, USA) supplemented with 10% fetal bovine serum (Sigma, St Louis, MO, USA).  
Expression plasmids and antibodies 
The expression vectors for wild-type RUNX3 and its deletion mutants have been previously 
described [82]. HA-CagA or HA-TRI(CA) expression vectors were kindly provided by Drs. 
Hatakeyama and Miyazono, respectively (Tokyo U., Japan). RUNX3 PY motif mutants and 
CagA WW domain deletion mutants were generated by Quikchange site-mutagenesis (Stratagene, 
San Diego, CA, USA) and confirmed by sequencing. Antibodies against CagA, RUNX3, Flag 
and His were purchased from Santa Cruz Biotechnology Inc (Santa Cruz, CA, USA). 
Preparation of recombinant proteins: GST-CagA and His-RUNX3 
Escherichia Coli BL21 cells were transformed with Glutathione-S-Transferase-CagA or 6-
Histidine-tagged-RUNX3 plasmid DNA, plated on LB agar containing ampicillin and then 
incubated overnight at 37°C. The following day, one colony was inoculated in 40ml of LB 
containing ampicillin overnight at 37°C with vigorous shaking. The resultant culture was diluted 
40 times and allowed to grow at 37°C with vigorous shaking to an Optical Density 600 (O.D.600) 
of 0.6. IPTG was then added to a final concentration of 0.5mM and incubated at room 
temperature for 4 hours with shaking to induce production of GST-CagA/His-RUNX3 protein in 
the BL21 bacterial cells. After 4 hours, the cells were pelleted by centrifugation and the pellet 
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was re-dissolved in GST binding buffer (100 mM NaCL, 50 mM Tris-HCL pH8.6, 1 mM MgCl2, 
1 mM EGTA) or His lysis buffer (50mM Tris pH8, 0.3M NaCl, 0.5% Triton X100, 20mM 
imidazole, 5mM b-mercaptoethanol) and sonicated on ice. Triton X-100 was added to a final 
concentration of 1% to the GST-CagA lysate. Both GST-CagA lysate and His-RUNX3 lysate 
were then centrifuged and the supernatant was decanted into a 50 ml conical tube and 50% slurry 
of GST-sepharose (Roche, Basel, Switzerland)/Nickel NTA (Qiagen, Venlo, Netherlands) beads 
was added to the supernatant and the mixture was rotated for 20 minutes at room temperature, 
following which the mixture was centrifuged. The supernatant was removed and the remaining 
beads were washed with GST binding buffer/His lysis buffer and then centrifuged as before. The 
process was repeated 3 times. GST-CagA beads were diluted to a 50% slurry and used for GST 
pull-down assays. His-RUNX3 fusion protein was eluted from the beads using 500μl His elusion 
buffer (50mM Tris pH8, 150mM NaCl, 0.5% Triton X100, 250mM imidazole, 5mM b-
mercaptoethanol), and concentration measured using Bradford’s Assay (Bio-Rad Technologies, 
Hercules, CA, USA).  
H. pylori culture and infection 
H. pylori NCTC11637 strain and its cagA-deficient isogenic mutant were purchased from ATCC 
and were cultured in bisulfite-free Brucella broth on agar media containing Ham’s F-12 medium 
supplemented with 10% FBS and 5µg/ml vancomycin at 37
o
C in the presence of 10% CO2. H. 
pylori was added to AGS cells for infection at an MOI of 50-100.  
Infection of mice with H. pylori  
INS-GAS mice were fed either WT H. pylori or cagA-deficient isogenic mutant H. pylori for 3 
days. Mouse gastric mucosa tissues were harvested after the 3 days of infection. Animal 
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experiments were done in Vanderbilt University School of Medicine, Nashville, Tennessee, USA, 
by Ms. A. Lamb, with help from Ms. J. Romero-Gallo and Dr. R. M. Peek, Jr. Experiments were 
approved by the Vanderbilt Institutional Animal Care and Use Committee.  
Immunohistochemistry for RUNX3 in mouse gastric mucosa tissues 
Staining was performed as described in [36] by Dr. Kosei Ito in University of Nagasaki, 
Nagasaki, Japan.  
Establishment of AGS cell lines stably expressing Flag RUNX3 
AGS cells were infected with retroviruses expressing vector control or Flag-RUNX3. Infected 
cells were selected with 2.5 g/ml puromycin (Sigma, St Louis, MO, USA) and the cells stably 
expressing RUNX3 were confirmed by immunoblotting. 
Transient transfection  
For experiments using HEK293T and COS7 cells, the cells were transfected using calcium 
phosphate method. For experiments using AGS cells, the cells were transfected using 
Lipofectamine 2000 according to the manufacturer’s protocol (Invitrogen, Carlsbad, CA, USA). 
Luciferase reporter assay  
AGS cells were transfected with Lipofectamine 2000 according to the manufacturer’s protocol 
(Invitrogen, Carlsbad, CA, USA) with 0.2 g of TRE3-luc [45], 0.2 g of TR-I(CA), 0.1 g of 
Flag-RUNX3, and the respective dosage of HA-CagA or its mutants with renilla luciferase 
reporter  as a control. HEK293T cells were transfected using calcium phosphate transfection 
method. 48 hr post-transfection, firefly and renilla luciferase activities were measured with the 
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dual luciferase assay system from Promega. Firefly luciferase activity was normalized to renilla 
luciferase activity. 
Whole cell lysis, immunoprecipitation and immunoblotting analysis  
Whole cell lyses were performed using lysis buffer (50 mM HEPES pH 7.4, 250 mM NaCl, 1 
mM EGTA, 1% NP-40, 1 mM PMSF, 1 x protease inhibitor cocktail tablet) for 20 minutes 4°C. 
Cell lysate was then either boiled with sodium dodecyl sulfate (SDS) loading buffer or used for 
pull-down or immunoprecipitation assays. For immunoprecipitation experiments, the cell lysates 
were incubated with anti-Flag or anti-HA antibodies-conjugated agarose beads for 2 hr at 4
o
C. 
All protein samples boiled with SDS loading buffer were analyzed by 10-13% SDS-
polyacrylamide gel electrophoresis (PAGE) gels and then transferred to nitrocellulose 
membranes for western blotting. Western blot membranes were incubated in 10% milk in PBS-
Tween, followed by incubation with appropriate primary antibody, then respective secondary 
antibody. Protein bands were visualized by anti-HA-horseradish peroxidase (HRP) followed by 
detection using an ECL detection kit.  
Pulse-chase analysis 
AGS or COS-7 cells were transfected with expression vectors for RUNX3 or RUNX3 together 
with CagA for 24 hr before being subjected to treatment with 100 g/ml of cycloheximide 
(Sigma, St Louis, MO, USA) for a period of 0, 1, 2 or 4 hr. Cells were then lysed and analyzed 





GST-CagA pull-down assay 
For glutathione-S-transferase (GST) pull-down assays, HEK293T cells were transfected 
respective plasmid DNAs for 48 hours and subjected to whole cell lysis protocol described above. 
20 μl of 50% GST-CagA-conjugated glutathione-Sepharose beads slurry was added to the lysate 
described above and the mixture was incubated on a rotator for 2 hour at 4°C. The precipitated 
proteins were then analyzed by immunoblotting with the appropriate antibodies as described 
















2.3.1 H. Pylori Infection Down-regulates RUNX3 Expression in a CagA-dependent Manner  
To explore the possibility that H. pylori infection might lead to the inactivation of 
RUNX3, we first investigated the effect of H. pylori infection on the transcriptional activity of 
RUNX3. RUNX3 activates the TRE luciferase reporter, which contains three RUNX binding 
sites [45], in the presence of constitutively activated TGF- type I receptor (TRI) in AGS cells 
(Figure 2.3a). However, the transcriptional activity of RUNX3 was inhibited by infection with 
wild-type (WT) H. pylori but not with its cagA-deficient isogenic mutant (Figure 2.3a), 
indicating that H. pylori down-regulates the transcriptional activity of RUNX3 and that CagA is 
essential for the inhibition. 
 
To further test whether CagA is sufficient to down-regulate the transcriptional activity of 
RUNX3, we examined the effect of CagA on the transcriptional activity of RUNX3 in the same 
TRE luciferase reporter assay. While co-transfection of CagA did not inhibit the basal activity 
induced by TRI in AGS cells, it inhibited the transcriptional activity of RUNX3 in a dose-
dependent fashion (Figure 2.3b). A similar inhibitory effect for CagA on RUNX3 was also 
observed in HEK293T epithelial cells, where RUNX3 displayed higher transcription activity 
than in AGS cells likely due to the higher transfection efficiency in these cells (Supplementary 
Figure 2.8 Pg 51-54). These data demonstrate that CagA alone is sufficient to inhibit the 
transcriptional activity of RUNX3. 
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Figure2.3 (a) CagA inhibits the transcriptional activity of RUNX3. AGS cells were transfected 
by Lipofectamine 2000 with TRE reporter plasmid together with expression vectors for 
RUNX3 and constitutively-activate TRI(CA) [45, 82] for 24 hr. Luciferase activity was 
measured 24 hr after the transfected cells were infected with WT or cagA-deficient H. pylori. 
Results represent the average of three independent experiments +/- SD. Figure2.3 (b) CagA is 
sufficient to inhibit the transcriptional activity of RUNX3. CagA, RUNX3 and TRI(CA) were 
co-transfected with the TRE reporter plasmid into AGS cells as indicated. 48 hr after 
transfection, luciferase activity was measured as in (a). 
 
Interestingly, examining the cellular levels of RUNX3 in H. pylori infected AGS cells 
revealed that the expression of RUNX3 was down-regulated by the infection in a CagA-
dependent manner (Figure 2.3c), indicating that CagA is involved in decreasing RUNX3 
expression. To further confirm this, we examined the expression of RUNX3 in H. pylori-infected 
MKN-45 cells, which express endogenous RUNX3. Infection of MKN-45 cells with WT but not 
the cagA-deficient H. pylori also decreased the expression of RUNX3 in MKN-45 cells (Figure 
2.3d). More importantly, when we investigated the expression of RUNX3 in H. pylori infected 
mice, we found that expression of RUNX3 in gastric mucosa was significantly reduced 48 h after 
infection with WT H. pylori (Figure 2.3e, left panel) compared to the expression either after 
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infection with the cagA-deficient H. pylori (Figure 2.3e, right panel) or in uninfected controls 
(data not shown). This time point precedes the development of gastric inflammation, further 
supporting a role for direct microbial effects in carcinogenesis. These in vivo data further support 
the conclusion that H. pylori infection reduces the expression of RUNX3 in a CagA-dependent 
manner. Supportively, co-expression of CagA with RUNX3 also decreased the cellular levels of 
RUNX3 (Figure 2.3f). The decreased expression of RUNX3 was due to the degradation of 
RUNX3, since treatment of the cells with proteasome inhibitor MG-132 reversed the decreased 
expression of RUNX3 (Figure 2.3f) and co-expression of CagA or infection with H. pylori did 
not alter the RUNX3 mRNA levels (Supplementary Figure 2.9&2.10). Collectively, these 
findings demonstrate that H. pylori CagA induces the proteolytic degradation of RUNX3.  
 
Figure 2.3 (c) CagA is essential for the reduced expression of RUNX3 in response to H. pylori 
infection. AGS cells transiently expressing RUNX3 were infected with WT and cagA-deficient 
H. pylori for 24 hr, and levels of RUNX3, CagA and phosphorylated CagA were detected by 
immunoblotting whole-cell extracts with anti-RUNX3, anti-CagA, anti-phosphotyrosine, or anti-
tubulin antibodies. Figure 2.3 (d) MKN-45 cells were infected with WT and cagA-deficient H. 






Figure 2.3 (e) RUNX3 expression is decreased within mouse gastric mucosa early after infection 
with H. pylori NCTC11637CagA positive strain. Immunohistochemistry for RUNX3 was 
performed on gastric mucosa harvested from INS-GAS mice infected with WT or cagA-deficient 
NCTC11637 H. pylori strains 48 h after inoculation. Representative staining of RUNX3 is 
shown for WT (left panel) or cagA-deficient mutant (right panel)-infected mice. The bars are 
equal to 100um.  
 
Figure 2.3 (f) CagA is sufficient to induce 
the proteasome-mediated degradation of 
RUNX3. AGS cells were transfected with 
expression vectors for Flag-RUNX3 and 
CagA-HA. 24 hr post-transfection, cells 
were treated or not with MG-132 (10 µM) 
for 6 hr. Whole-cell lysates were 
immunoblotted for the expression of 
RUNX3, CagA and tubulin as indicated.  
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2.3.2 RUNX3 Interacts with CagA through the PY Motif and the WW Domain Respectively. 
 The CagA-dependent degradation of RUNX3 by H. pylori infection prompted us to 
examine whether CagA might directly target RUNX3. Immunoprecipitation of CagA from 
transfected HEK293T cells co-immunoprecipitated RUNX3 (Figure 2.4a). The interaction 
between CagA and RUNX3 was further confirmed with the in vitro GST pull-down 
(Supplementary Figure 2.11), indicating a direct interaction between RUNX3 and CagA. 
Furthermore, when the physical interaction between CagA and the endogenous RUNX3 was 
investigated in H. pylori-infected RUNX3-expressing MKN45 gastric cancer cells, RUNX3 co-
immunoprecipitated CagA after H. pylori infection (Figure 2.4b). These data demonstrate that 
CagA associates with RUNX3 in vitro and in vivo in response to H. pylori infection. 
 
Figure 2.4 (a) CagA interacts with RUNX3 in transfected cells. HEK293T cells were transfected 
with Flag-RUNX3 and HA-tagged CagA as indicated. The transfected HEK293T cell lysates 
were incubated with anti-HA antibodies-conjugated agarose beads. CagA-HA 
immunoprecipitates from whole-cell lysates were immunoblotted for Flag-tagged RUNX3. 
Figure 2.4 (b) CagA interacts with RUNX3 after H. pylori infection. MKN45 gastric cancer 
cells were infected with H. pylori for 0 or 24 hr. Endogenous RUNX3 was immunoprecipitated 
from H. pylori-infected MKN45 cells with either anti-IgG or anti-RUNX3 antibodies and 
immunoblotted for associated CagA with anti-CagA antibodies. 
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In order to define the region of RUNX3 responsible for its interaction with CagA, we 
performed an in vitro GST pull-down assay using cell lysates containing various deletion 
mutants of RUNX3 (Figure 2.4c). Full-length RUNX3 as well as two of its C-terminal deletion 
mutants (deleted to amino acid 325) were able to associate with CagA (Figure 2.4c). Further 
deletion to amino acid 283 abolished RUNX3’s interaction with CagA (Figure 2.4c), indicating 




Figure 2.4(c) The region of RUNX3 from amino acids 283 to 325 is important for its interaction 
with CagA. Left: Schematic showing the domain structure of RUNX3 and the position of the PY 
motif. Right: GST-CagA was incubated with cell lysates containing Flag-tagged RUNX3 or its 
various deletion mutants as indicated and precipitated with glutathione agarose beads. The 
recovered materials were immunoblotted with anti-Flag antibodies.
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Examining the sequence from amino acids 283 to 325 revealed that this region contains a 
PPxY sequence (known as the PY motif), which can be recognized by a WW domain within an 
interacting partner protein [108]. The WW domain is defined by a conserved tryptophan (W) 
residue and an invariant proline (P) residue placed approximately 20-22 amino acid residues 
apart [108]. Interestingly, in examining the sequence of CagA, we identified two WW domain-
like sequences within the N terminal region of CagA (designated as WW1 and WW2, 
respectively) (Figure 2.4e). We then explored the possibility that the PY motif of RUNX3 and 
the WW domains of CagA might be involved in their interaction. We generated various mutants 
of RUNX3 or CagA with mutation or deletion of the PY motif or the WW domains and 
examined their interaction. When the first proline (P) of the PPPY sequence was mutated to 
alanine (A) (designated as RUNX3-P1A) or the PPPY sequence was deleted (designated as 
RUNX3-∆PY), the interaction of CagA with RUNX3 was significantly impaired (Figure 2.4d), 
indicating that the PY motif is critical for the interaction of RUNX3 with CagA.  
 
Figure 2.4 (d) PY motif of RUNX3 is essential for its interaction with CagA. HEK293T cells 
were transfected with HA-tagged CagA and WT Flag-RUNX3 or its PY motif mutants as 
indicated. CagA-HA immunoprecipitates were immunoblotted for the associated RUNX3 WT or 




As for the CagA WW domain deletion mutants, deletion of WW1 of CagA barely 
affected its interaction with RUNX3 (Figure 2.4e). However, deletion of WW2 domain alone or 
together with WW1 completely abolished its interaction with RUNX3, confirming that the 
interaction between RUNX3 and CagA is through the specific recognition of the PY motif by the 
WW domain.  
 
 
Figure 2.4 (e) WW domain 2 of CagA is critical for its interaction with RUNX3. Top: Schematic 
showing the relative location of the two WW domains of CagA and the sequence alignment of 
the WW domains of CagA with other known WW domains. Bottom: HEK293T cells were 
transfected with HA-tagged CagA or its WW domain deletion mutants and Flag-RUNX3 as 




2.3.3 Interaction between RUNX3 and CagA Reduces RUNX3 Stability. 
Having identified that CagA interacts with RUNX3, we next investigated whether the 
recognition of the PY motif by the WW domain of CagA was required for the down-regulation 
of the transcriptional activity of RUNX3. When the effect of CagA on the activity of RUNX3 
WT or PY motif mutants was examined, we found that RUNX3-P1A and RUNX3-∆PY 
displayed resistance to CagA-induced inhibition (Figure 2.5a). Furthermore, when the 
capabilities of the CagA WW domain deletion mutants to down-regulate RUNX3 were tested in 
the TRE reporter assay, CagA with the deletion of WW1, WW2, or both barely inhibited the 
activity of RUNX3 (Figure 2.5b). These results demonstrate that the interaction with CagA is 
critical for the inactivation of the transcriptional activity of RUNX3.  
 
Figure 2.5 (a) RUNX3 with PY motif mutations is resistant to CagA-mediated down-regulation 
of its activity. WT RUNX3 or its PY motif mutants, CagA and TRI(CA) were co-transfected 
with the TRE reporter plasmid into HEK293T cells as indicated. Luciferase activity was 
measured as in Figure 2.3.1b. Figure 2.5 (b) WW domains of CagA are essential for the down-
regulation of the transcriptional activity of RUNX3. WT or WW domain deletion mutants of 
CagA, RUNX3 and TRI(CA) were co-transfected with the TRE reporter plasmid into 
HEK293T cells as indicated. Luciferase activity was measured as in (a). 
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Next, we determined whether the interaction between RUNX3 and CagA is essential for 
the degradation of RUNX3. We first compared the effect of WT CagA on the stability of 
RUNX3 by measuring the half-life of WT RUNX3 or its PY motif mutants. Consistent with the 
notion that CagA promotes the degradation of RUNX3, the half-life of RUNX3 was reduced 
from greater than 4 hr to about 1.5 hr when CagA was co-expressed with RUNX3 (Figure 2.5c). 
Conversely, RUNX3 PY motif mutants were more resistant to CagA-induced degradation, with 
much longer half-lives (greater than 3 hr for RUNX3-P1A and greater than 4 hr for RUNX3-
∆PY) (Figure 2.5c), indicating that the PY motif is important for the CagA-induced degradation 
of RUNX3.  
 
Figure 2.5 (c) The PY motif is important for the CagA-induced degradation of RUNX3. COS-7 
cells were transfected using calcium phosphate with WT RUNX3 with or without CagA, or with 
RUNX3-P1A or RUNX3-∆PY and CagA as indicated. 24 hr after transfection, cells were treated 
with 100 g/ml of cycloheximide (CHX) for the indicated time points, and immunoblotted for 
the expression of Flag-RUNX3. A representative result from three independent experiments is 
shown in the left panels. Quantification of the results is shown in the right panel. Data represent 




Additionally, when the half-life of RUNX3 was measured with CagA WW domain 
deletion mutants, we found that the half-life of RUNX3 was moderately reduced when co-
transfected with either WW1 or WW2 deletion mutants (Figure 2.5d). CagA with the deletion of 
both WW1 and WW2 domains failed to affect the half-life of RUNX3 (Figure 2.5d). Collectively, 
these data support the idea that CagA reduces the stability of RUNX3 via the specific recognition 
of the PY motif by the WW domain of CagA.  
 
Figure 2.5 (d) WW domains of CagA are critical for CagA-induced degradation of RUNX3. 
COS-7 cells were transfected with RUNX3 together with WT CagA or its WW domain deletion 
mutants as indicated. 24 hr after transfection, cells were treated with CHX for indicated time 
points, immunoblotted for the expression of Flag-RUNX3, and levels were quantified as 
described in (c).  
 
2.3.4 CagA stimulates the ubiquitination of RUNX3 in vivo.  
Since CagA stimulates the degradation of RUNX3 (Figure 2.3), we next investigated 
whether CagA promoted the ubiquitination of RUNX3, an event that is required for proteasome-
mediated degradation. When we examined the ubiquitination of endogenous RUNX3 in MKN-
45 cells in response to H. pylori infection, we found that WT but not cagA-deficient H. pylori 
induced the ubiquitination of endogenous RUNX3 (Figure 2.6a), suggesting that CagA is 
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essential for the H. pylori-induced ubiquitination of RUNX3. When RUNX3 was co-transfected 
with ubiquitin and the ubiquitination of RUNX3 was measured, we found that co-expression of 
CagA significantly enhanced the ubiquitination of RUNX3 (Figure 2.6b), indicating that CagA is 
sufficient to promote the ubiquitination of RUNX3 
 
 
Figure 2.6 (a) H. pylori infection induces the ubiquitination of RUNX3 in a CagA-dependent 
manner. MKN-45 cells were infected with WT H. pylori NCTC11637 and its cagA
-
 isogenic 
mutant. 24 h after infection, cells were treated with MG-132 (10µM) for another 24 h. 
Endogenous RUNX3 immunoprecipitates were immunoblotted for ubiquitination with anti-Ub 
antibodies (upper panel). Levels of CagA and RUNX3 are shown in the lower two panels. 
Figure 2.6 (b) CagA enhances ubiquitination of RUNX3 in vivo. HEK293T cells were 
transfected with the indicated combination of plasmids expressing Flag-RUNX3, His-ubiquitin, 
and CagA-HA. RUNX3 immunoprecipitates were immunoblotted for ubiquitination with anti-
His antibodies (upper panel). Levels of RUNX3 and CagA are shown in the lower two panels.  
  
We next assessed roles for the PY motif of RUNX3 and the WW domains of CagA in the 
CagA-induced ubiquitination of RUNX3. First, we examined the ubiquitination of RUNX3 PY 
motif mutants. Compared to WT RUNX3, the CagA-induced ubiquitination of RUNX3-P1A and 
RUNX3-∆PY was significantly impaired, with RUNX3-∆PY showing greater reduction in the 
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levels of ubiquitination (Figure 2.6c). These data are consistent with the findings that the PY 
motif is required for CagA-mediated degradation of RUNX3 (Figure 2.6d). When the WW 
domain mutants of CagA were examined for their abilities to induce the ubiquitination of 
RUNX3, we observed that deletion of WW1 moderately reduced CagA-induced ubiquitination of 
RUNX3 (Figure 2.6d). All together, these data further support the conclusion that the mutual 
interaction between CagA and RUNX3 is essential for the CagA-induced ubiquitination and 
subsequent degradation of RUNX3.  
 
 
Figure 2.6 (d) WW domains of CagA are important for enhanced ubiquitination of RUNX3 by 
CagA. HEK293T cells were transfected with the indicated combination of plasmids expressing 
Flag-RUNX3, His-ubiquitin, and CagA-HA or its WW domain deletion mutants. Ubiquitination 








Loss of RUNX3 expression is associated with gastric carcinogenesis [47], and 
hypermethylation of the RUNX3 promoter or mis-localization of the RUNX3 protein largely 
attributes to the inactivation of RUNX3 in gastric cancer cells and gastric tumors [47, 82]. H. 
pylori infection has been shown to be an independent risk factor for the methylation of the 
promoter of RUNX3 [109, 110]. Nevertheless, CagA appears to not be important for this 
epigenetic regulation [110]. In our current study, we demonstrate a CagA-dependent direct 
inactivation of RUNX3 in epithelial cells. CagA-induced degradation of RUNX3 in gastric 
epithelial cells provides another mechanism for the inactivation of RUNX3 and might account 
for the initiation of gastric cancer. While H. pylori-induced degradation of RUNX3, which is 
CagA dependent, might represent an immediate cellular response to infection, chronic infection 
with H. pylori might eventually induce the methylation of the RUNX3 promoter, which is CagA 
independent, and account for the permanent inactivation of RUNX3. 
 
CagA induces the ubiquitination and degradation of RUNX3 in cultured cells (Figures 2.3 & 
2.5). How does CagA in fact induce the ubiquitination of RUNX3? First, CagA might function as 
an E3 ligase that directly targets RUNX3 for ubiquitination. Like many E3 ligases, CagA 
contains two WW domains (Figure 2.4e). However, cysteine, which is the essential amino acid 
for an E3 ligase to form a thioester bond with ubiquitin [111], is not found within CagA, 
excluding the possibility that CagA itself is an E3 ligase. Therefore, it is likely that CagA 
functions as a scaffold protein to recruit an E3 ligase for the ubiquitination of RUNX3. Further 
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investigation is needed to determine the E3 ubiquitin ligase that is utilized by CagA for the 
ubiquitination and proteasome-dependent degradation of RUNX3. 
 
There are two WW domains (WW1 and WW2) within the N-terminal region of CagA 
(Figure 2.4e); however, these two domains appear to function differently regarding their 
involvements in the down-regulation of RUNX3. WW2, not WW1, is required for the specific 
interaction with the PY motif since deletion of WW2 but not WW1 abolished CagA’s interaction 
with RUNX3 (Figure 2.4e). Although not directly involved in the interaction with RUNX3, 
WW1 is also important for the effective down-regulation of RUNX3. Deletion of WW1 impairs 
CagA’s ability to induce ubiquitination and degradation of RUNX3, and to inhibit its 
transcriptional activity (Figures 2.5b, d and 2.6d). Therefore, it is quite possible that CagA 
utilizes its WW2 to associate with the PY motif of RUNX3 and its WW1 to recruit the ubiquitin 
E3 ligase for the degradation of RUNX3.  
 
Emerging data demonstrate that transcription factor RUNX3 functions as a gastric tumor 
suppressor by regulating the expression of a variety of genes. It activates p21, Bim or Claudin-1 
to attenuate cell growth, induce cell apoptosis or suppress tumor growth, respectively [55, 56, 
112]. In addition, RUNX3 inhibits VEGF to suppress angiogenesis and metastasis of human 
gastric cancer [113]. H. pylori infection down-regulates the transcriptional activity of RUNX3 in 
a CagA-dependent manner (Figure 2.3a). Specific binding of the WW domain to the PY motif of 
RUNX3 is critical for the down-regulation of the transcription activity of RUNX3 (Figure 2.5a & 
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b). Through down-regulating the transcriptional activity of RUNX3, CagA might influence many 




 mice strongly suggest its tumor suppressor function in gastric cancer. 
Runx3
-/-
 mice displayed hyperplasia in gastric epithelial cells, and these cells were insensitive to 
the growth-inhibiting effects of TGF- [47]. Recent studies from Ohnishi et al. demonstrate that 
transgenic mice expressing CagA also displayed gastric epithelial hyperplasia, and some of the 
mice developed gastric polyps as well as adenocarcinoma of the stomach and small intestine 
[101], emphasizing the oncogenic role of CagA in gastric cancer. Although the oncogenic 
potential of CagA relies on its ability to regulate the function of multiple host proteins, 
immunohistostaining from mice infected with H. pylori (Figure 2.3e) indicates that gastric 
epithelial hyperplasia might partially result from the inactivation of RUNX3 by CagA in the 
gastric epithelial cells. It might also be interesting to determine the levels of RUNX3 in gastric 
epithelial cells from CagA transgenic mice. 
 
CagA interacts with various host cellular proteins to trigger distinct signaling pathways. 
Most cellular proteins targeted by CagA are cytoplasmic signaling molecules.  For example, 
CagA associates with cytoplasmic SHP-2 or PAR1, respectively, for cell morphology or 
epithelial apical-basal polarity changes [102, 103]. CagA also indirectly regulates the activation 
of a variety of transcription factors, including NF-B and NFAT, by its association with 
upstream cytoplasmic signaling molecules [114]. Interestingly, in our current study, we found 
that CagA directly associated with the nuclear transcription factor RUNX3, via CagA’s WW 
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domain and RUNX3’s PY motif, and induced its degradation (Figure 2.3 & 2.5). The location of 
this CagA-induced degradation is unknown, but our preliminary data suggested that it could 
possibly happen in the nuclear, since infection with H. pylori or co-expression of CagA does not 
change the nuclear localization of RUNX3 (Supplementary Figure 2.14). Supporting this, CagA 
was also found in the nuclear fraction of H. pylori-infected AGS cells (Supplementary Figure 
2.15). These data suggest a potential nuclear function of CagA. In addition to its ability to 
interact with and regulate cytoplasmic proteins, CagA might also be able to enter the nucleus and 
regulate the functions of nuclear proteins. The probable nuclear localization of CagA has to be 
further characterized and studied.  
 
Furthermore, signaling pathways involving CagA can be tyrosine phosphorylation-dependent 
and -independent manners [104, 114, 115]. Down-regulation of RUNX3 by CagA seems to be 
phosphorylation-independent, since a phosphorylation-deficient mutant of CagA was still able to 
induce the ubiquitination and degradation of RUNX3 (Supplementary Figures 2.12 & 2.13). 
 
The identification of gastric tumor suppressor RUNX3 as a novel cellular target by CagA 
provides a mechanism for the carcinogenesis of CagA. The specific recognition of the PY motif 
of RUNX3 by the WW domain of CagA defines a novel interaction of a host protein with CagA 
(Figure 2.7). All these studies will contribute to the better understanding of the molecular 
mechanism for the initiation of gastric cancer. Regulation of the interaction between RUNX3 and 




Figure 2.7 Schematic model for the role of CagA in H. pylori infection-induced degradation of 
RUNX3. After injection into cells, CagA associates with the PY motif of RUNX3 via its WW2 
domain. Binding of CagA to RUNX3 recruits an unidentified E3 ligase (E3 X) and initiates the 
ubiquitination and proteasome-mediated degradation of RUNX3, resulting in the inactivation of 










2.5 Supplementary Figures 
 
Figure 2.8 CagA inhibits the transcriptional activity of RUNX3 in HEK293T cells. CagA, 
RUNX3 and TRI(CA) were co-transfected with the TRE reporter plasmid into HEK293T cells 
as indicated. 48 hr after transfection, luciferase activity was measured as in Figure 2.3.1b. 
 
Figure 2.9 mRNA expression of RUNX3 is not affected by CagA. AGS cells were transfected 
with Flag-RUNX3 and CagA for 48hr before total RNA was extracted and quantitative real-time 





Figure 2.10 H. pylori infection does not alter the mRNA expression of RUNX3. AGS cells were 
transfected with Flag-RUNX3 for 24 hr followed by H. pylori infection for 24 hr before total 
RNA was extracted and the mRNA level was quantified as in Supplementary Figure 2.  
 
Figure 2.11 CagA interacts with RUNX3 in vitro. GST or GST-CagA was incubated with 
recombinant RUNX3 and precipitated with glutathione agarose beads. The recovered materials 
were immunoblotted with anti-RUNX3 antibodies. CBB: Coomassie brilliant blue staining. His-






Figure 2.12 CagA induces the degradation of RUNX3 independent of its tyrosine 
phosphorylation. AGS cells were transfected with expression vectors for Flag-RUNX3, WT 
CagA (CagA-HA) or phosphorylation-deficient mutant of CagA (CagA-PR-HA) for 48 hr. 




Figure 2.13 CagA induces the ubiquitination of RUNX3 independent of its tyrosine 
phosphorylation. HEK293T cells were transfected with expression vectors for Flag-RUNX3, 






Figure 2.14 H. pylori infection reduces the nuclear expression of RUNX3. AGS cells stably 
expressing RUNX3 were infected with H. pylori for the indicated time points, and fractionated 
into cytoplasmic and nuclear fractions. Levels of RUNX3 were detected by immunoblotting 
fractions with anti-RUNX3 antibodies. Levels of tubulin or HDAC1 as cytoplasmic or nuclear 
fractionation controls are also shown. 
 
 
Figure 2.15 H. pylori CagA localizes in both nucleus and cytoplasm. AGS cells were infected 
with H. pylori at the indicated time points, and fractionated into cytoplasmic and nuclear 
fractions. Levels of CagA were detected by immunoblotting fractions with anti-CagA antibodies. 














Chapter 3:  
Peptidyl-prolyl cis/trans isomerase 
Pin1 inhibits tumor suppressor activity 









3.1 Introduction: The prolyl Isomerase Pin1 in Breast Development and Cancer. 
Pin1, a peptidyl-prolyl isomerase (PPIase) that specifically isomerizes only 
phosphorylated proline (P) directed serine (S) or threonine (T) bonds (S/T-P), is found to be a 
key signaling molecule involved in breast development and breast cancer [116]. A study in 2001 
indicated that Pin1 was over expressed in an estimated 75% of primary human breast cancer 
tissues. Especially in grade II and III tumors, the mean expression level of Pin1 in cancer 
specimens was about 10 times higher than those of normal tissue controls. Moreover, Pin1 
expression level was also higher in cell lines derived from human breast cancer than in cell lines 
established from normal mammary epithelial cells, emphasizing on Pin1’s possible link to 
mammary carcinogenesis [117].  
 
The human Pin1 gene was the first PPIase to be found essential for cell division in yeast 
and human cells, being identified from a yeast genetic screen searching for proteins involved in 
mitotic regulation [118]. Pin1 is unique in that, unlike typical PPIases, Pin1 only bind to the S/T-
P bond after phosphorylation of the S/T residue [118-120]. The binding is followed by catalysis 
of the intrinsically rather slow cis to trans isomerization of peptide bonds N terminal of the 
proline residues. This isomerization process affects folding or refolding of the substrate protein, 
inducing conformation changes to regulate the function of the protein. These conformational 
changes can affect phosphorylation status, protein-protein interactions, subcellular localization or 




Figure 3.1 From [124]. Shows phosphorylation dependent regulatory mechanism carried 
out by Pin1. Proteins are first phosphorylated by proline-directed kinases like CDKs, MAPKs, 
GSK-3β allowing the binding of Pin1. Step two shows subsequent isomerization of the substrate 
by Pin1, inducing conformational changes resulting in a different function of the target protein.  
 
In tandem with its over-expression in breast cancer, Pin1 is found to be capable of 
stimulating multiple oncogenic pathways at different levels contributing to mammary 
carcinogenesis. For example, over-expression of Pin1 in breast cancer cells results in the 
degradation of promyelocytic leukemia protein (PML), a tumor suppressor protein, that regulate 
multiple cellular pathways including DNA damage repair, apoptosis and cell cycle regulation. 
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Degradation of PML by Pin1 seemed to prevent hydrogen peroxide induced death in MDA-MB-
231 breast cancer cells, increasing their proliferation, contributing to the cancer phenotype [121]. 
 
Pin1 has been reported to increase cyclin D1 gene expression by activating multiple 
pathways, including JNK/Ras pathway, Nuclear Factor (NF)-κB signaling pathway as well as 
Wnt/β-catenin signaling [117, 125-127]. Cyclin D1 has a well established role in the 
development of breast epithelial cells, it is known regulate cell cycle G1/Synthesis phase 
progression and is important for cell proliferation [128]. It is also found to be over-expressed in 
more than 50% of human breast cancer specimens, making it a strong prognostic factor for 
human breast cancer [129, 130]. Interestingly, in more than 80% of the tumors over-expressing 
cyclin D1, Pin1 expression level was also high [117]. Furthermore, Pin1
-/-
 female mice showed 
similar phenotypes to cyclin D1 knockout mice, with under developed mammary epithelial duct 
and reduced mammary gland expansion during pregnancy [131]. All these data suggest that 
perhaps one of the major methods through which Pin1 is involved breast development is through 
the regulation of cyclin D1 function.  
 
Pin1 has also been shown to play a role in the activation of Notch1, as a transcription 
factor which is deregulated in many cancers including breast cancer. Pin1 increases the 
transformation-inducing potential of Notch1 in soft-agar assays [123]. In addition, over-
expression of Pin1 is correlated to centrosome amplification, which occurs frequently in many 





Figure 3.2 From [133]. Figure shows the different ways in which Pin1 catalyzed prolyl 
isomerization can regulate protein functions and result in a spectrum of target activities.  
  
A recent study in 2009 linked Pin1 to the TGF-β signaling pathway. Pin1 was described 
to inhibit TGF-β-induced transcription and gene expression by mediating the degradation of 
Smad2/3 proteins via Smurf2-mediated ubiquitin-proteasome degradation. RUNX3 is an 
important downstream regulator in the TGF-β signaling pathway, and a target substrate of 
Smurf2 [134]. Based on the fact that Pin1 expression is highly up-regulated in breast cancer 
while RUNX3 is largely inactivated in breast cancer and also due to both proteins’ involvement 
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in the TGF-β signaling pathway, we believe that perhaps the over-expression of Pin1 plays a role 
in RUNX3 inactivation.  
 
In this part of the thesis, we showed that there is a significant inverse correlation between 
RUNX3 and Pin1 in breast cancer specimens. Pin1 interacts specifically with RUNX3, targeting 
it for proteasome degradation. Identification of Pin1 as a novel regulator of RUNX3 will better 















3.2 Materials and Methods 
Cell culture  
Transformed mammary epithelial cells were purchased from ATCC (Manassas, VA, USA). 
MCF-7, MDA-MB-157, MDA-MB-361, MDA-MB-231 and MDA-MB-468 were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) (Sigma, St Louis, MO, USA), supplemented 
with 10% fetal bovine serum (FBS) (Sigma, St Louis, MO, USA). Hs587T was maintained in 
DMEM supplemented with 0.01ng/ml of bovine serum (Sigma, St Louis, MO, USA). Hcc70 and 
T-47D were propagated in RPMI-1640 (Sigma, St Louis, MO, USA) with 10% FBS, the medium 
for T-47D was further supplemented with 0.2 Units/ml of Bovine insulin (Sigma, St Louis, MO, 
USA). BT-20 was cultured in a 1:1 mixture of DMEM and Ham's F12 medium (Sigma, St Louis, 
MO, USA) with 10% FBS added. Normal mammary epithelial tissues MCF-12A was maintained 
in a 1:1 mixture of DMEM and Ham's F12 medium, 20 ng/ml Human epidermal growth factor 
(Cell Signaling, Danvers, MA, USA), 100 ng/ml cholera toxin (Sigma, St Louis, MO, USA), 
0.01 mg/ml bovine insulin and 500 ng/ml hydrocortisone (Sigma, St Louis, MO, USA), and 5% 
horse serum (Sigma, St Louis, MO, USA). HEK293T cells were maintained in DMEM 
supplemented with 10% FBS.  
Plasmids 
The expression vectors for wild-type RUNX3 and its deletion mutants have been previously 
described [82]. HA-TRI(CA) expression vector was kindly provided by Dr Miyazono (Tokyo 
U., Japan). GST-Pin1 was kindly provided by Dr. H.-Y.Kao (Case Western Reserve University). 
Flag-Pin1 and Myc-Pin1 vectors were constructed from GST-Pin into pcDNA-Flag/Myc vectors. 
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Flag-Pin1 C115A, W34A, and RUNX3 S/T-P mutants were generated using Quikchange site-
mutagenesis (Stratagene, San Diego, CA, USA) and confirmed by sequencing.   
Antibodies 
Antibodies against Flag, HA, Myc, ubiquitin were purchased from Santa Cruz Biotechnology Inc 
(Santa Cruz, CA, USA). Antibody against Pin1 was purchased from R&D systems (Minneapolis, 
MN, USA), and antibody against RUNX3 was from Abcam (Cambridge, MA, USA). 
GST-Pin1-conjugated glutathione-Sepharose beads 
GST-Pin1 is purified from Escherichia Coli BL21 cells as stated in the protocol from Chapter 
2.2: Preparation of recombinant proteins: GST-CagA and His-RUNX3. 
Human tissue samples and immunohistochemistry 
Paraffin blocks of mastectomy specimens from a total of 80 invasive ductal carcinomas were 
obtained from the pathology department of the National University Hospital, Singapore after 
approval of ethical issues by the Domain Specific Research Board of the National Health Care 
Group (NHG) of Singapore (approval code B06/006). Immunostaining was performed as in [33], 
by Mr. C W Ong and Dr M Salto-Tellez at Cancer Science Institute, National University of 
Singapore.  
Establishment of MCF-7 cell lines stably expressing Flag RUNX3 and Flag RUNX3-4A  
MCF-7 cells were infected with retroviruses expressing vector control or Flag-RUNX3 or Flag-
RUNX3-4A. Infected cells were selected with 2.5 g/ml puromycin (Sigma, St Louis, MO, USA) 
and the cells stably expressing RUNX3 WT and its mutant were confirmed by immunoblotting. 
 63 
 
SiRNA Treatment, immunoprecipitation and immunoblotting analysis 
Pin1 SiRNA or negative control SiRNA (Ambion, Inc. Austin, TX, USA) was transfected into 
MCF-7 cells and MDA-MB-361 cells using Lipofectamine 2000  according to the 
manufacturer’s protocol (Invitrogen, San Diego, CA, USA). Immunoprecipitation and 
immunoblotting analysis were performed as previously described in Chapter 2.2: Whole cell 
lysis, immunoprecipitation and immunoblotting analysis. 
Transient transfection and the luciferase reporter assay  
MCF-7 cells were transfected with Fugene HD according to the manufacturer’s protocol (Roche, 
Basel, Switzerland) with 0.5 g of TRE3-luc [45], 0.5 g of TR-I(CA), 0.25 g of Flag-
RUNX3, and respective dosage of Flag-Pin1 WT or its mutants. HEK293T cells were transfected 
using calcium phosphate transfection method. 48 hr post transfection, firefly and renilla 
luciferase activities were measured with the dual luciferase assay system from Promega 
(Madison, WI, USA). When Pin1 inhibitor, PIB (Sigma, St Louis, MO, USA), was used, 2μM of 
the drug was added for 48 hr prior to luciferase assay.  
GST pull-down Assay 
293T cells were transfected with the indicated expression vectors using the calcium phosphate 
method for 48 hr. Cell lysates were then incubated in vitro with 20μl of agarose beads containing 
GST-Pin1 or GST at 4
o
C for 2 hr. The precipitated proteins were subjected to SDS-PAGE 





Pulse Chase Analysis 
HEK293T cells were transfected with the indicated combination of expression vectors for 
RUNX3 and Pin1 for 24 hr before being subjected to treatment with cycloheximide (Sigma, St 
Louis, MO, USA) to a final concentration of 100ng/ml for a period of 0, 1, 2, or 4 hr. Cells were 
lysed and analyzed with immunoblotting for the expression of RUNX3 with anti-RUNX3 
antibodies.  
Quantitative real time PCR 
RUNX-MCF-7 cells were transfected with Flag-Pin1 or pcDNA3.1 empty vector for 48 hr before 
total RNA was extracted using RNeasy Mini Kit (Qiagen, Venlo, The Netherlands). 
Complementary DNA was synthesized with Omniscript RT kit (Qiagen, Venlo, The Netherlands) 
and quantitative real-time PCR was performed using Qiagen SYBR green PCR kit by 7300 real-











3.3.1 RUNX3 Levels Inversely Correlates with Pin1 Levels in Human Breast Cancer 
Tissues 
Since Pin1 is highly over-expressed in breast cancer while RUNX3 is regularly either not 
expressed or mis-localized to the cytoplasm in breast cancer, we investigated whether Pin1 is 
involved in this inactivation of RUNX3. To address this question, we first used 
immunohistochemistry to examine the possible pathological correlation between Pin1 and 
RUNX3 expression levels in breast cancer and normal patient samples. We analyzed 80 human 
breast ductal carcinoma specimens from Singapore and found that over 80% of samples (19 out 
of 23) with low or no expression of RUNX3 displayed high expression of Pin1. Conversely, 
approximately 77% of samples (46 out of 59) with high expression of RUNX3 had low levels of 
Pin1 (Figure 3.3a and b). Statistical analysis revealed an inverse correlation between the 
expression of RUNX3 and Pin1 in these cancer specimens with a Spearman coefficient for 
correlation (RUNX3 and Pin1) of -0.615 (p<0.01) (Figure 3.3b).  
 
To further explore the possible relationship between expression levels of RUNX3 and 
Pin1, we examined the expression of RUNX3 and Pin1 in a panel of cell lines that includes non-
tumorigenic breast epithelial cells and breast cancer cell lines. Pin1 appeared to be highly 
expressed in the breast cancer cell lines, while not expressed in the non-tumorigenic MCF-12A 
cell line. Although the expression level of RUNX3 varied across cell lines, the overall expression 







Figure 3.3 (a and b) Correlation between RUNX3 and Pin1 levels in human breast cancers and 
normal tissues. (a) Representative immunohistochemical staining of RUNX3 and Pin1 using α-
RUNX3 and α-Pin1 antibodies in normal and tumor breast tissues. Boxed Regions enlarged 
below. Their correlation was analyzed by Spearman rank correlation test (p<0.01) (b). (c) 
Comparison of Pin1 and RUNX3 levels in mammary epithelial cell lines. The same amount of 
total lysates prepared from either normal human mammary epithelial cell lines or carcinoma-





To better examine the correlation between Pin1 levels and RUNX3 expression, we 
determined the effects of Pin1 inhibition on RUNX3 expression in a breast cancer cell line, 
MCF-7, that stability expresses RUNX3 (hereby known as RUNX3-MCF-7) and in another 
breast cancer cell line, MDA-MB-361, that expresses endogenous RUNX3. Both cell lines 
express endogenous Pin1. Inhibition of Pin1 through siRNA knockdown showed increased 
exogenous RUNX3 expression in the stable line RUNX3-MCF-7, as compared to the control 
(Figure 3.3d). Likewise, siRNA knockdown of Pin1 in MDA-MB-361 resulted in an increase in 
endogenous RUNX3 expression (Figure 3.3e), indicating that RUNX3 expression level is 
dependent on Pin1 expression. These results suggest that Pin1 might inactivate RUNX3 through 
suppression of its expression level.  
 
 
Figure 3.3 (d and e) RUNX3 expression level is rescued by Pin1 down-regulation. RUNX3-
MCF7 cell line stably expression RUNX3 in (d) and MDA-MB-361 cell line endogenously 
expressing RUNX3 and Pin1 in (e) were transfected with Pin1 siRNA or control. Whole cell 






3.3.2 Pin1 interacts with RUNX3 in a phosphorylation-dependent manner.  
To explore whether Pin1 down-regulates RUNX3 expression directly, we investigated if 
RUNX3 is a direct substrate of Pin1. Flag-Pin1 and Myc-RUNX3 were co-expressed 
exogenously in HEK293T cells, and immunoprecipitation using anti-Flag antibody-conjugated 
beads was performed on the whole cell lysates. Pin1 was found to interact with RUNX3 in vivo 
(Figure 3.4a). The physical interaction between RUNX3 and Pin1 was also investigated using 
MDA-MB-157 cells that endogenously express RUNX3 and Pin1. RUNX3 was co-
immunoprecipitated with Pin1 and not IgG, indicating that RUNX3 and Pin1 does interact 
endogenously (Figure 3.4b). To further confirm this interaction, RUNX3 was over-expressed in 
HEK293T cells and the cell lysates were harvested for a pull-down assay with either GST or 
GST-Pin-conjugated beads. RUNX3 was only pulled down together with GST-Pin1 beads, 
displaying the in vitro interaction of RUNX3 and Pin1 (Figure 3.4c).  
 
Figure 3.4 (a) Exogenously expressed RUNX3 and Pin1 interacts in vivo. HEK293T cells were 
transfected with Myc-RUNX3 and Flag-Pin1 expression vectors. Cell lysates were 
immunoprecipitated with M2-Flag agarose and immunoblotted with Myc and Flag antibodies. 
Figure 3.4 (b) RUNX3 and Pin1 interact endogenously.  MDA-MB-157 cell lysates were 
immunoprecipitated with Pin1 or control IgG antibody and subjected to western blotting with 




Figure 3.4 (c) RUNX3 and Pin1 interacts in vitro. HEK293T cell lysates over-expressing 
RUNX3 protein were subjected to GST-Pin1 fusion protein pull-down assay. The precipitates 
from the pull-down were then immunoblotted with Flag and GST antibodies.   
 
Since Pin1 is known to bind selectively to motifs containing a phosphorylated serine or 
threonine residue preceding a proline residue as previously discussed, we tested whether the 
interaction between Pin1 and RUNX3 is also phosphorylation dependent. HEK293T cells were 
transfected with Flag-RUNX3 plasmids and the whole cell lysates were treated with a calf 
intestinal alkaline phosphatase (CIP) prior to a GST pull-down assay and tested for Pin1 binding 
ability. Expectedly, treatment with phosphatase almost completely abolished the interaction 
between RUNX3 and Pin1, hinting at a phosphorylation dependent interaction between the two 
proteins (Figure 3.4d). In addition, to assess the possibility that this phosphorylation dependent 
interaction could be due to pS/T-P motifs in RUNX3, we used a mitotic phosphospecific 
antibody MPM2, which specifically recognizes phosphorylation events in these motifs [119, 
135]. As shown in Figure 3.3.2e, RUNX3 was co-precipitated with the MPM2 antibody, 





Figure 3.4 (d) RUNX3 and Pin1 interact in vitro in a phosphorylation dependent manner. 
HEK293T cell lysates over-expressing RUNX3 protein were treated with CIP prior to GST pull-
down- assay as in (c). The precipitates from the pull-down were immunoblotted with Flag and 
GST antibodies.   
 
 
Figure 3.4 (e) RUNX3 protein contains pS/T-P motif. Cell lysates from RUNX3-MCF7 stable 
line was immunoprecipitated with control IgG antibody or anti-MPM2 antibody and 






3.3.3 RUNX3 interacts with Pin1 through 4 unique S/T-P motifs 
To further understand the mechanism of RUNX targeting by Pin1, we went on to map the 
interaction sites on Pin1 and RUNX3. Pin1 is known to consist of an N-terminal WW domain 
and a C-terminal catalytic PPIase domain. The WW domain forms a binding pocket, binding 







 and Tryptophan (W)
34
 [136]. Point mutations of any of one the substrates (mutants S16A, 
R17A, W34A Figure 3.5a) have been shown to interfere with Pin1 substrate binding ability. The 
PPlase domain on the other hand contains a cysteine (C) residue which is important for the 
catalysis of the cis-trans isomerization of the peptide bond in pS/T-P motifs of Pin1 substrates. 
Mutation of the cysteine (mutant C115A Figure 3.5a and b) in the PPIase domain to an alanine 
has been shown to abolish the catalytic activity of Pin1 without interfering with the Pin1’s 
interaction with its substrate protein [136]. 
 
To investigate if RUNX3 binds to the WW domain of Pin1, we performed a GST pull-
down assay as previously described using either wild-type (WT) GST-Pin1 or GST1-Pin1 with 
the respective point mutations. Expectedly, RUNX3 interacted with WT GST-Pin1, but failed to 
show interaction with both S16A and W34A (Figure 3.5a and b). Weak binding was only 
observed in RUNX3’s interaction with GST-Pin1-R17A mutant (Figure 3.5a), while mutation of 
the PPIase cysteine did not abolish RUNX3 and Pin1 binding (Figure 3.5a). These results 







Figure 3.5 (a and b) Specific binding of RUNX3 to the WW domain in Pin1. HEK293T cells 
over-expressing RUNX3 protein is subjected to GST pull-down assay with various GST-Pin1 
mutants (a). In (b), HEK293T cells were co-transfected with Myc-Pin1 WT or W34A mutant and 
Flag-RUNX3. Cell lysates were immunoprecipitated with M2-Flag agarose and immunoblotted.  
 
As mentioned in Chapter 1.2, Figure 1.1, RUNX3 has a PST (proline, serine, threonine) 
rich region after the Runt domain from amino 185 to 415. To identify the specific S/T-P motif/s 
in RUNX3 that is/are interacting with the WW-domain of Pin1, we first tried to identify the 
region of RUNX3 that is involved in the interaction. HEK293T cells were transfected with either 
full length RUNX3 (1-415) or c-terminal deletion mutants of Flag-RUNX3 (Figure 3.5c left), 
cell lysates were then subjected to GST-pull-down assay with WT-GST-Pin1. Full-length 
RUNX3 and deletion mutants, 1-373, 1-325 and 1-234 all showed significant degrees of 
interactions with GST-Pin1, interaction with Pin1 was only abolished with the 1-187 mutant 
(Figure 3.5c right). This in vitro interaction data indicates that Pin1 binds largely to RUNX3 






Figure 3.5 (c) Region of RUNX3 from amino acid 187 to 234 is important for interaction with 
Pin1. Left: shows schematic representation of RUNX3 domains and the position of amino acids 
187 to 234. Right: GST-Pin1 was incubated with HEK293T cell lysates containing Flag-tagged 
RUNX3 or its various deletion mutants as indicated and precipitated with glutathione agarose 
beads. The recovered materials were immunoblotted for RUNX3 with anti-RUNX3 antibodies. 
CBB= Coomasie blue blot.  
 
Detailed analysis of RUNX3 amino acids 187 to 234 revealed 4 unique S/T-P motifs at 
locations 209, 212, 214 and 231 (Figure 3.5d top). Point mutations were made on these 4 S/T-P 
motifs, specifically, T209A, T212A, S214A and T231A. A final mutant containing all point 
mutations on all 4 S/T-P motifs listed above was also generated and named RUNX3-4A. GST-
pull-down assay was done using WT-RUNX3 and the above 5 S/T-P mutants with WT-GST-
Pin1. Interestingly, we noticed that GST-Pin1 was able to interact with all 4 single point 
mutation mutants, T209A, T212A and S214A and T231A (Figure 3.5d). Only when all 4 S/T-P 
motifs were mutated did we see an abolishment of Pin1 binding to RUNX3 (Figure 3.5d). This 
 74 
 
data showed redundancy in the S/T-P binding sites, suggesting that perhaps all four S/T-P motifs 
identified between regions 187 to 234 of RUNX3 were able to bind to Pin1. An in vivo co-
immunoprecipitation assay further confirmed that mutation of all 4 S/T-P binding site disrupted 
RUNX3’s interaction with Pin1 (Figure 3.5e), indication that Pin1 interacts with RUNX3 
through 4 unique S/T-P motifs on RUNX3.  
 
 
Figure 3.5 (d and e) 4 unique S/T-P motifs in RUNX3 are important for binding to Pin1. (d) Top: 
Positions of the 4 S/T-P motifs in RUNX3 region 187 to 234. Bottom: HEK293T cell lysates 
over-expressing the various RUNX3 S/T-P point mutations were subjected to GST-Pin1 pull 
down assay and immunoblotted as in (c). (e) HEK293T cells transfected with Flag-RUNX3 WT 
or mutant containing point mutations of all four S/T-P motif and Myc-Pin1 is 





3.3.4 Pin1 disrupts the function of RUNX3 
   To further study the physiological significance of Pin1 targeting of RUNX3, we studied 
if Pin1 inhibits the transcriptional activity of RUNX3. Using HEK293T cells, RUNX3 was found 
to activate the TβRE luciferase reporter in the presence of constitutively active TGF-β type 1 
receptor (TβRI) [45]. However, this transcriptional activity was inhibited in a dose dependent 
manner in the presence of increasing dosage of WT Pin1, while remaining relatively unchanged 
with increasing dosage of the enzymatic deficient Pin1 mutant, C115A, indicating that Pin1 
down-regulates the transcriptional activity of RUNX3 in an enzymatic dependent manner (Figure 
3.6a). The W34A mutant which has reduced interaction with RUNX3 was only able to inhibit the 
transcriptional activity of RUNX3 to a small extend (Figure 3.6a). Likewise, WT Pin1 was 
unable to reduce the transcriptional activity of RUNX3-4A mutant that does not interact with 
Pin1 (Figure 3.6b). It is also interesting to note that RUNX3-4A has a reduced transactivational 
ability compared to WT-RUNX3 (Figure 3.6b).   
 
The ability of Pin1 to disrupt the transcriptional activity of RUNX3 is further confirmed 
through luciferase assay in a physiologically relevant breast cell line, MCF-7. The activation of 
TβRE luciferase reporter in the presence of TβRI by RUNX3 was inhibited by Pin1 but not Pin1-
C115A mutant in MCF-7 (Figure 3.6c). The addition of PiB, an inhibitor of the isomerase 
activity of Pin1 (Figure 3.6c), reversed the inhibition of RUNX3 activity by Pin1, supporting the 





Figure 3.6 (a) Pin1 inhibits the transcriptional activity of RUNX3. HEK293T cells were 
transfected with TRE reporter plasmid together with expression vectors for RUNX3, 
constitutively activated TRI(CA) [45, 82], and increasing doses of Pin1 WT and its different 
mutants as indicated. In each experiment, cells were also co-transfected with Renilla luciferase 
reporter plasmid which was used as an internal control. Luciferase activity was measured 48 hr 
after transfection and results represent the average of three independent experiments +/- SD.  (b) 
Pin1 inhibits the transcriptional activity of RUNX3 but not RUNX3-4A. HEK293T cells were 
transfected with TRE reporter plasmid, expression vectors for RUNX3 WT or mutant 4A, 




Figure 3.6 (c) Pin1 inhibits the 
transcriptional activity of RUNX3 in MCF7 
cells. MCF7 cells were transfected and 
luciferase assay performed as in (a). Cells 
were also treated with PIB (2.0μM) for 48 




RUNX3 as a transcription factor is known to recruit co-activators like p300 and 
synergistically transactivate downstream genes [58]. RUNX3 activated the pGL3-12-RXE 
luciferase promoter, which contains 12 copies of RUNX3 binding sites [58] in the presence of 
p300. This activation was again inhibited by WT Pin1 but not the enzymatic inactive mutant 
Pin1-C115A (Figure 3.6 c). Pin1 was unable to inhibit the transcriptional activity of the Pin1 
binding deficient mutant, RUNX3-4A, once again confirming the notion that Pin1 inhibits the 
transcriptional activity of RUNX3 in an enzymatic and binding dependent manner.  
 
Figure 3.6 (d) Pin1 inhibits the cooperation between co-activator p300 and RUNX3. HEK293T 
cells were transfected with pGL3-12-RXE Luc [58] together with expression vectors for RUNX3, 
p300 and increasing doses of Pin1 WT and enzymatic deficient mutant. Luciferase assay 
performed as in (a). Figure 3.6 (e) Pin1 and RUNX3 interaction is important to inactivate the co-
activation of p300 and RUNX3. HEK293T cells were transfected with pGL3-12-RXE Luc and 
expression vectors for RUNX3 WT or 4A mutant, p300 and Pin1 WT. Luciferase assay 





3.3.5 RUNX3 stability is reduced in the presence of Pin1 
 The inverse correlation between RUNX3 and Pin1, as well as the ability of Pin1 to 
directly disrupt the function of RUNX3 prompted us to investigate whether Pin1 might regulate 
the stability of RUNX3. We over-expressed WT Pin1 and the enzymatic deficient mutant Pin1 
C115A in RUNX3-MCF-7 stable lines and examined the effect of Pin1 on the expression of 
RUNX3 by immunoblotting. As expected, the expression of RUNX3 was down-regulated in the 
presence of WT Pin1 but not enzymatic deficient Pin1 C115A (Figure 3.7 a). This decreased in 
RUNX3 expression in the presence of Pin1 was reversed by treatment with increasing dosage of 
proteasome inhibitor MG-132 (Figure 3.7b). Moreover, quantification of RUNX3 mRNA level 
through real-time PCR showed that RUNX3 mRNA levels were not affected by the presence of 
Pin1 in the cells (Figure 3.7c), suggesting that Pin1 reduces the expression of RUNX3 at the 
protein level rather than at the mRNA level and that Pin1 does regulate the stability of RUNX3 
protein.  
Figure 3.7 (a) Pin1 reduces the expression of RUNX3. RUNX3-MCF-7 cells were transiently 
transfected with either Pin1 WT plasmid or C115A enzymatic deficient mutant. Levels of 
RUNX3 were detected by immunoblotting the whole-cell extracts with anti-Flag antibodies. 
Figure 3.7 (b) Pin1 induces proteasome-mediated degradation of RUNX3. RUNX3-MCF-7 
stable line was transfected with Pin1 expression vector. 24h post transfection, cells were treated 
with increasing dosage of MG132 as indicated for 10h. Cell lysates were then immunoblotted for 




Figure 3.7 (c) Pin1 does not alter the mRNA expression of RUNX3. RUNX3-MCF-7 cells were 
transfected with Flag-Pin1 for 48 hours before total RNA was extracted. Complementary DNA 
was synthesized and quantitative real-time PCR was performed. Expression of RUNX3 mRNA 
was normalized with the expression of hGAPDH.  
 
Subsequently, we also looked at whether interaction between Pin1 and RUNX3 is 
necessary to reduce stability of RUNX3. We co-expressed either WT RUNX3 or RUNX3-4A 
mutant in MCF-7 cells in the presence of Pin1 and immunoblotted for the expression of RUNX3. 
Not surprisingly, Pin1 was only able to down-regulate the expression of WT RUNX3 but not 
RUNX3-4A (Figure 3.7d), indicating that interaction between RUNX3 and Pin1 is necessary for 
the degradation of RUNX3 by Pin1.  
 
  
Figure 3.7 (d) Interaction between RUNX3 
and Pin1 is important for degradation of 
RUNX3. MCF-7 cells were transiently 
transfected with Flag-RUNX3 WT or 4A 
and Pin1 WT expression vectors. Cell 
lysates were immunoblotted as in (a).  
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Figure 3.7 (e) Stability of RUNX3 is reduced in the presence of Pin1. HEK293T cells were 
transfected with WT RUNX3 with or without Pin1 WT or Pin1 C115A, or with RUNX3-4A and 
Pin1 WT as indicated. 24 hr after transfection, cells were treated with CHX (10μg/ml) for the 
indicated time points, and immunoblotted for the expression of Flag RUNX3. A representative 
result from three independent experiments is shown in the left panel. Quantification of the results 
is shown in the right panel. Data represent the average of three independent experiments.  
 
To more quantitatively evaluate the effect of Pin1 on the stability of RUNX3, we 
compared the half-life of over-expressed RUNX3 in the presence of WT Pin1 and enzymatic 
deficient Pin1 C115 in HEK293T cells. We performed the pulse-chase experiment using 
cycloheximide to inhibit the synthesis of new RUNX3 protein (Figure 3.7e left). RUNX3 was 
found to be relatively stable in HEK293T cells with a half life of greater than 4 hours, however, 
in the presence of Pin1, the degradation of RUNX3 was accelerated and the half-life of RUNX3 
was reduced to about 2 hours. Conversely, the enzymatic deficient Pin1-C115A protein did not 
increase the degradation of RUNX3 significantly, in the presence of Pin1-C115A, the half-life of 
RUNX3 was also estimated to be greater than 4 hours (Figure 3.7e right). We also quantified the 
half-life of RUNX3-4A mutant in the presence and absence WT Pin1. We observed that 
RUNX3-4A has a much shorter half life (2.5 hours) than WT RUNX3, but the presence of Pin1 
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did not shorten this half-life further (Figure 3.7e). These data demonstrate that Pin1 reduces the 
stability of RUNX3 in an enzymatic and interaction dependent manner, by targeting RUNX3 for 
proteasome degradation.  
 
3.3.6 Pin1 induces the ubiquitination of RUNX3. 
Since Pin1 mediates proteasome degradation of RUNX3, we next investigated if Pin1 
also induce the ubiquitination of RUNX3. RUNX3 was co-transfected with ubiquitin and WT 
Pin1 or enzymatic deficient Pin1 C115A in HEK293T cells, and the ubiquitination of RUNX3 
was measured. We found that RUNX3 ubiquitination was enhanced in the presence of WT Pin1 
but not the enzymatic deficient mutant, indicating that Pin1 promote the ubiquitination of 





Figure 3.8 (a) Pin1 enhances ubiquitination 
of RUNX3 in vivo. HEK293T cells were 
transfected with indicated combination of 
plasmids expressing Flag-RUNX3, Ha-
ubiquitin and Myc-Pin1 WT and C115A. 
RUNX3 immunoprecipitates were 
immunoblotted for ubiquitination with anti-
Ha antibodies in the upper panel. Levels of 
RUNX3 and Pin1 are shown in the lower 




We also looked at the importance of Pin1 and RUNX3 interaction in the Pin1 induced 
ubiquitination of RUNX3. We co-transfected WT RUNX3 or RUNX3-4A in the presence and 
absence of WT Pin1. As expected, Pin1 was only able to significantly enhance the ubiquitination 
of WT RUNX3 but not RUNX3-4A mutant that is unable to bind to Pin1. This indicates that 
interaction of RUNX3 and Pin1 is important for the Pin1-induced RUNX3 ubiquitination, and is 
consistent with previous findings that Pin1’s binding to RUNX3 is necessary for proteasome 
degradation of RUNX3.  
 
Figure 3.8 (b) Interaction between Pin1 and RUNX3 is important for enhancement of RUNX3 
ubiquitination by Pin1. HEK293T cells were transfected with a combination of Flag-RUNX3 
WT or 4A, Ha-ubiquitin and Myc-Pin1 WT as indicated. RUNX3 ubiquitination is detected as in 
(a) 
 
To better examine the consequence of Pin1 on RUNX3 ubiquitination, we determined the 
effect of Pin1 inhibition on RUNX3 ubiquitination in 2 physiological relevant cell lines: 
RUNX3-MCF-7 and MDA-MB-361. SiRNA knock down of Pin1 in both RUNX3-MCF-7 cell 
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line and MDA-MB-361 cell line showed a marked decrease in the exogenous and endogenous 
ubiquitination levels of RUNX3 respectively, indicating that the level of RUNX3 ubiquitination 
is dependent on the expression level of Pin1 in the cells. In conclusion, these data support the 
notion that Pin1 binds to RUNX3, isomerizes the S/T-P bonds in RUNX3 resulting in Pin1-
induced ubiquitination of RUNX3 and subsequent degradation of the RUNX3 protein.  
 
 
Figure 3.8 (c and d) Down-regulation of Pin1 enhances the ubiquitination of RUNX3. RUNX3-
MCF-7 cell line stably expression RUNX3 in (c) and MDA-MB-361 cell line endogenously 
expressing RUNX3 and Pin1 in (d) were transfected with Pin1 siRNA or control. Cells were 
treated with 20μM of proteasome inhibitor, MG132, for 8 h prior to immunoprecipitation 
experiment. RUNX3 immunoprecipitates were immunoblotted for ubiquitination using anti-








Pin1 has been shown to be involved in a number of oncogenic pathways [116, 124, 133], 
its over-expression is observed in 75% of breast cancer specimens, and high Pin1 levels also 
correlates with poor prognosis [117]. In this part of the thesis, we identified tumor suppressor 
RUNX3 as a novel substrate for Pin1. Our data showed that expression of Pin1 and RUNX3 
played an inverse correlation in breast cancer samples, and over-expression of Pin1 stimulated 
proteasome degradation of RUNX3, thus decreasing the transcriptional activity of RUNX3. 
Since RUNX3 functions as a breast cancer tumor suppressor as previously defined by Huang et 
al., our data that shows the inactivation of RUNX3 by Pin1 may well be a new mechanism by 
which Pin1 contributes to mammary oncogenesis.  
 
Through the study of a large cohort breast cancer patient samples, we have identified a 
significant inverse correlation between the expression of Pin1 and RUNX3 (Figure 3.3a and b). It 
is interesting to note that this inverse correlation is most significant in the early stages (stage I 
and II) of breast cancer. It is possible that in early stages of breast cancer, one of the first major 
mechanisms for inactivation of RUNX3 is by Pin1-induced proteasome degradation of RUNX3. 
In the later stages of cancer, we saw a reduced inverse correlation between the two proteins 
because inactivation of RUNX3 at the stage is thought to be more permanent, and could be done 
through hypermethylation of the RUNX3 promoter. The biological significance of this inverse 
correlation is further confirmed through the up-regulation of RUNX3 expression after Pin1 
inhibition (Figure 3.3d and e).  
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The interaction between Pin1 and RUNX3 was identified by both in vitro and in vivo 
experiments with exogenous and endogenous proteins (Figure 3.4). Since Pin1 is known to 
specifically bind to and isomerizes phosphorylated S/T-P bonds, we confirmed that the 
interaction between Pin1 and RUNX3 is phosphorylation dependent (Figure 3.4d) and that 
RUNX3 does contain phosphorylated S/T-P motifs (Figure 3.4e). The interaction between 
RUNX3 and Pin1 is mediated by the WW domain of Pin1 (Figure 3.5a and b), which is also 
known to bind other target substrates. The substrate binding pocket of the WW domain, in 
















 to Alanine disrupts the interaction between 
Pin1 and RUNX3. However, while the S16A and W34A mutations seem to completely abolish 
binding, the R17A mutant is still able to bind minimally to RUNX3.  We also identified that 
RUNX3 binds to Pin1 through 4 unique S/T-P motifs between the regions 187-234 (Figure 3.5c, 
d and e). RUNX3 and Pin1 interaction is only disrupted after mutations of all 4 S/T-P binding 
sites, indicating that Pin1 binds redundantly to these four binding sites. It is possible that Pin1 
binds to each of the 4 different S/T-P motifs on RUNX3 to affect different downstream target 
activity of RUNX3.  
 
Our data show that Pin1 abolishes the transcriptional activity of RUNX3 (Figure 3.6). As 
previously discussed, inactivation of RUNX3 can happen through a number of mechanisms, 
including hemizygous deletion of the RUNX3 gene, hypermethylation of the RUNX3 promoter 
and mis-localization of the RUNX3 protein to the cytoplasm [34, 47, 82]. From our study, in 
addition to human breast cancer specimens showing an inverse correlation between expression of 
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Pin1 and RUNX3, co-expression of Pin1 and RUNX3 in breast epithelial cells MCF-7 also 
showed a decrease in RUNX3 protein expression level (Figure 3.7a) without any changes in 
RUNX3 mRNA level (Figure 3.7c) This down-regulation in RUNX3 expression can be rescued 
by proteasome inhibitor, MG132 (Figure 3.7b), and Pin1 also induced the ubiquitination of 
RUNX3 protein (Figure 3.8). These data indicate that Pin1 inactivates RUNX3 by inducing its 
ubiquitination and targets it for proteasome degradation. It is important to note that Pin1 is the 
second protein we have identified after CagA to inactivate RUNX3 by causing its degradation 
through the 26S proteasome. Although the precise mechanism of Pin1-induced RUNX3 
ubiquitination is unknown, Pin1 is known to induce the ubiquitination of Smad2/3 proteins 
enhancing the interaction between Smad2/3 with their E3 ligase Smurf2 [134]. Since RUNX3 is 
also a substrate of Smurf2 [46, 58], we have reasons to believe that Pin1 might mediate 
ubiquitination in RUNX3 through the recruitment of Smurf2. It is possible to immunoprecipitate 
Pin1 and RUNX3 complex and subject the immunoprecipitates to mass spectrometry analysis to 
see if Smurf2 is also a component of the complex.  
 
Interestingly, the phosphorylation deficient RUNX3 mutant, RUNX3-4A, which does not 
bind to Pin1, seems to function like a positive model for Pin1 inactivation of RUNX3. Despite its 
inability to bind to (Figure 3.5d and e) and be modified by Pin1, RUNX3-4A has reduced 
transcriptional activity compared to WT RUNX3 (Figure 3.6e) and is less stable than WT 
RUNX3, with a much shorter half life (Figure 3.7e). Furthermore, even in the absence of Pin1, 
RUNX3-4A is much more ubiquitination compared WT RUNX3 (Figure 3.8b). To better explain 
this phenotype of the RUNX3-4A protein, we look at the ubiquitination of RUNX3 protein. It 
has been observed that the region of RUNX3 between amino acids 187 and 375 is important for 
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the stability of the RUNX3 protein [58]. Ubiquitination occurs at lysine residues within RUNX3, 





 [58]. These two lysine residues are surprisingly close to the 4 S/T-P motifs (from amino 
acids 209 to 231) that Pin1 binds to on RUNX3. Since a phosphate group is rather large in size, 
phosphorylation of all 4 S/T-P motifs from amino acids 209 to 231 may clutter the regions on 
RUNX3 surrounding the 4 S/T-P motifs, resulting in the region becoming inaccessible to post-




 are unreachable to E3 ligases and 
cannot be ubiquitinated. This will subsequently result in increase protein stability of RUNX3. 
When Pin1 binds to RUNX3 through the 4 S/T-P motifs, it changes the conformation of RUNX3, 
perhaps putting it into a more accessible conformation, allowing E3 ligases to reach the lysine 
sites, leading to proteasome degradation of RUNX3, hence inactivating RUNX3. The RUNX3-
4A mutant, because of the lack of phosphate clusters, and also the fact that alanine is smaller 
than serine or threonine, the protein is possibly in a more “open” confirmation than WT RUNX3, 
allowing ubiquitination of the lysine residues in RUNX3-4A, hence decreasing its protein 
stability.  
 
To further elucidate Pin1’s regulation of RUNX3, it is also necessary to identify the 
kinase that is involved in phosphorylating RUNX3 at the 4 S/T-P motifs. One such candidate 
would be the homeodomain-interacting kinase 2 (HIPK2). HIPK2 is known to be the regulator of 
a large number of transcription factors including p53, CtBP and RUNX1 [137-140]. HIPK2 is 
needed for activation of the tumor suppressor activity of p53, it phosphorylates p53 at Serine
53
 to 
induce apoptosis during DNA damage [139]. RUNX1 is phosphorylated by HIPK2 at proline-
directed serine and threonine residues in its C-terminus. Furthermore, RUNX1 proteins bearing 
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leukemogenic mutations could not be phosphorylated by this mechanism, indicating that HIPK2 
phosphorylation is essential for the function of RUNX1 [137, 138]. Since RUNX proteins are 
highly conserved, it would be interesting to find out if HIPK2 too plays a role in the 
phosphorylation of the proline directed serine/threonine residues in RUNX3. Phosphorylation of 




Figure 3.9 Schematic model for the inactivation of RUNX3 by Pin1. RUNX3 is phosphorylated by 
a kinase at the S/T-P motifs. In the presence of Pin1 up-regulation, Pin1 binds to RUNX3 
through the WW domain and S/T-P motifs respectively, resulting in a conformational change in 
the structure of RUNX3. RUNX3 then undergoes Pin1-induced ubiquitination and is targeted to 
the 26S proteasome for degradation.  
 
In conclusion, our data shows that Pin1 inactivates tumor suppressor protein RUNX3 in 
breast carcinomas by binding 4 unique S/T-P motifs on RUNX3, inducing ubiquitination of the 
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protein and targeting it for degradation (Figure 3.9). At the moment, there is support for the 
development of Pin1-specific inhibitors as therapeutic anti-cancer drugs [116, 117, 123, 132]. 
Through its down-regulation of the activity of tumor suppressor RUNX3, we propose a new 
mechanism by which Pin1 contributes to oncogenesis and provide additional support of the 










































RUNX3 is a transcription factor that regulates lineage-specific gene expression in 
developmental processes and is involved in the formation of a variety of cancers [141]. RUNX3 
is most widely studied in its role as a tumor suppressor in gastric cancer. It elicits its tumor 
suppressor functions by controlling the expression of many genes involved in the growth, 
apoptosis, and differentiation of gastric epithelial cells [55, 56, 62] as well as genes involved in 
angiogenesis and cell junctions [57, 113]. RUNX3 is expressed in glandular stomach epithelial 
cells, and loss of expression of RUNX3 is causally related to genesis and progression of gastric 
cancer and also correlates with differentiation, metastasis, and poor prognosis of gastric cancer 
[47, 142, 143]. A study in 2002 found that knocking out Runx3 in mice lead to hyperplasia of the 
gastric epithelium, an early developmental step in carcinogenesis [47]. Furthermore, it was found 
that 90% of human gastric cancer samples showed reduced levels of RUNX3 expression due to 
hemizygous deletion, hypermethylation of its promoter, or protein mis-localization [47, 82]. The 
inactivation of RUNX3 appears to occur both at an early stage as well as during progression of 
gastric cancer [47, 82] and its expression correlates with the stage of the cancer; fewer late-stage 
tumors expressed RUNX3 than early-stage tumors [47]. While emerging evidence suggests that 
RUNX3 is a tumor suppressor whose inactivation is involved in the initiation and progression of 
gastric cancer, the trigger for RUNX3 inactivation within the cells is largely unknown.  
 
Meanwhile, RUNX3 was also found to be inactivated in breast carcinomas. RUNX3 
mRNA and protein expression were found to be lowered due to hypermethylation of the Runx3 
promoter. In breast cancer specimens that still expressed RUNX3, the RUNX3 protein showed 
cytoplasmic re-localization. RUNX3 was also found to have tumor suppressor activity in breast 
cancer when the same researchers showed that injection of nude mice with stable clones of a 
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MDA-MB-231 breast cancer cell line expressing a control vector resulted in tumor formation 
whereas nude mice that were injected with MDA-MB-231 cells expressing RUNX3 did not 
developed tumors [34]. Subsequently, our lab also defined a role for RUNX3 as a tumor 
suppressor in ERα-positive breast cancer whereby RUNX3 down regulates the expression of 
ERα. Enhanced ERα expression is associated with increased breast cancer risk, therefore 
inactivation of RUNX3 results in increase ERα stability and enhances cell proliferation in 
response to circulating estrogens [33].  
 
RUNX3 functions as an important gatekeeper of cell differentiation and proliferation and 
its inactivation is perhaps crucial to the initiation of carcinogenesis in many tissue types. Study 
of the regulation of RUNX3 in these tissues will give us insight into the process of 
carcinogenesis and presents new therapeutic targets for potential treatment of the different 
cancers. In this thesis, we focus on the understanding of RUNX3 inactivation in gastric cancer by 
H. pylori infection as well as the targeting of RUNX3 by Pin1 in breast carcinomas.  
 
It is important to study gastric cancer because worldwide, gastric cancer is the fourth 
most diagnosed cancer and the second most common cause of cancer-related death. It is 
estimated that 10,570 people will die from gastric cancer in 2010 in the United States alone [144]. 
Intestinal-type adenocarcinomas, which occur primarily in the distal regions of the stomach, 
predominate in countries where gastric cancer is more common. Diffuse-type adenocarcinomas 
occur more frequently in younger populations [145]. Adenocarcinomas of the stomach are often 
not diagnosed until they have metastasized to other tissues, which makes their prognoses very 
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poor [146]. Mucosa-associated lymphoid tissue lymphomas comprise a small proportion of 
gastric cancers, and tend to respond very well to treatment. Gastric carcinogenesis is a complex, 
multistep and multifactorial event and like all cancers many etiological factors contribute to the 
development and progression of gastric cancer. These can include the activation of oncogenes, 
inactivation of tumor suppressors, diet, tobacco use, and infection with Helicobacter pylori [73] . 
 
H. pylori is the only bacterium classified by the World Health Organization as a Type I 
carcinogen, with an estimated 63% of all stomach cancers caused by infection with the bacterium 
[73]. The gram-negative spirochete persistently colonizes the mucosa of the stomach, where it 
may attach directly to the epithelial cells. Over half the world’s population is infected with H. 
pylori, though the wide majority of these infections are symptomless. However, significant 
pathologies are found in the minority, including chronic gastritis, peptic ulcer disease, and gastric 
cancers [147]. Infection is most commonly associated with intestinal-type gastric 
adenocarcinoma, though infection can also lead to the development of non-Hodgkin’s or MALT 
lymphomas [147]. Many proposed mechanisms for its pathogenicity exist, including infection-
induced cell proliferation, epithelial cell elongation and loss of polarity, and degradation of cell–
cell junctions. Recent publications together with my study in Chapter 2 indicate that H. pylori 
infection is important in the inactivation of RUNX3 by both protein degradation and promoter 
hypermethylation [110, 148]. Therefore, inactivation of RUNX3 might be another critical 




Ubiquitination of Runt family proteins have long been described but the physiological 
significance of this process is not well defined [149]. Studies indicate that ubiquitination-
dependent proteolytic degradation of RUNX3 is an important regulatory mechanism for 
controlling its tumor suppressor activity [46]. Ubiquitination is a series of reactions mediated by 
three different enzymes including E1, E2 and E3. Ubiquitination is activated by ubiquitin 
activating enzyme E1. Activated ubiquitin is transferred to ubiquitin conjugating enzyme E2 and 
is further transferred to the substrates by the ubiquitin E3 ligase. Of all three enzymes, only E3 
ligase confers the substrate specificity [150]. Several E3 ligases for RUNX3 ubiquitination have 
been identified. For example, RUNX3 is ubiquitinated by Smurfs (Smad ubiquitin regulator 
factor) and Smurfs-mediated ubiquitination of RUNX3 reduced the stability and activity of 
RUNX3 [58]. Additionally, RUNX3 has been shown to be a target of MDM2, an E3 ligase 
known for the tumor suppressor p53, indicating an oncogenic surveillance function of RUNX3 
[151]. 
 
Our study in Chapter 2 indicates that H. pylori infection induces the ubiquitination and 
degradation of RUNX3. Infection of H. pylori leads to reduced cellular levels of RUNX3 in 
cultured gastric epithelial cells as well as in gastric epithelial cells of infected mice. The reduced 
expression of RUNX3 appears to be derived from H. pylori-induced ubiquitination and 
degradation of RUNX3. Interestingly, H. pylori-induced degradation of RUNX3 is virulence 
factor CagA-dependent since wild-type but not cagA-deficient H. pylori strain down-regulates 
the cellular levels of RUNX3 [148] 
 95 
 
Virulence factor CagA is encoded by pathogenesis island cagPAI of H. pylori, which also 
encodes a type IV secretion system. The 120-140 kDa CagA is injected into host epithelial cells 
via type IV secretion system [73]. Within the cells, CagA interacts with different intracellular 
host proteins to elicit its many roles in the pathogenesis of H. pylori. For example, CagA 
associates with and activates cytoplasmic protein tyrosine phosphatase SHP-2, resulting in 
cytoskeletal reorganization, cell elongation and cell scattering, and the “hummingbird” 
phenotype [102, 152]. CagA also associates with TAK1 to activate NF-B and modulate NF-B-
dependent inflammatory response [153]. Through its association with various host proteins, H. 
pylori CagA is actively involved in H. pylori-induced gastric carcinogenesis. The ability of H. 
pylori to induce degradation of RUNX3 also relies on specific interaction of CagA with RUNX3. 
CagA directly interacts with RUNX3 in vivo and in vitro. More importantly, the interaction is 
mediated by specific recognition of PPxY (Py) motif of RUNX3 by WW domain of CagA. 
Blocking the interaction either by mutation of Py motif or deletion of WW domain reduces the 
ability of CagA to induce ubiquitination and degradation of RUNX3, emphasizing on the 
importance of this interaction in the degradation of RUNX3 [148].  
 
The WW domain has been found in a variety of E3 ligases and is involved in the binding 
of these E3 ligases to their substrates [154]. One possibility how CagA can induced 
ubiquitination of RUNX3 is that CagA could be an E3 containing intrinsic ligase activity. 
However, the cysteine residue, which is the essential amino acid for an E3 ligase to form a 
thioester bond with ubiquitin [111], is not found within CagA. This raises another possibility that 
CagA might function as a scaffold protein to recruit an E3 ubiquitin ligase for the ubiquitination 
and degradation of RUNX3. Supporting this, we found that CagA immunoprecipitates from 
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transfected cells were able to ubiquitinate RUNX3 in vitro (unpublished data). It has to be noted 
that two WW domains, defined as WW1 and WW2, were identified within the N-terminal region 
of CagA. Although both WW domains of CagA are involved in ubiquitination and degradation 
of RUNX3, only WW2 of CagA is essential for CagA’s interaction with Py motif of RUNX3. 
Currently, it is not clear why CagA needs two WW domains for the ubiquitination and 
degradation of RUNX3 but only one WW domain for the specific interaction. It is possible that 
WW2 is involved in the interaction with RUNX3 while WW1 is involved in the recruitment of 
an E3 ligase. However, the identity of the E3 ligase remains to be further characterized. Several 
E3 ligases, including Smurfs and MDM2, have been identified for the ubiquitination of RUNX3 
(Jin et al ., 2004), it will be interesting to investigate whether any of them is actually involved in 
the CagA-induced degradation of RUNX3.  
 
There are evidences from my study in chapter 2 that show that this CagA-induced 
degradation of RUNX3 may occur in the nucleus. The degradation of RUNX3 might in fact pose 
as a novel nuclear function for CagA, although this novel function has to be better characterized. 
By and large, CagA exists as a cytoplasmic protein, we also have to consider the possibility of 
CagA-induced degradation in the cytoplasm. It is probable that binding of CagA to RUNX3 
might facilitate cytoplasmic localization of RUXN3, which may result in degradation of RUNX3 
in cytoplasm. Jun-activation domain-binding protein 1 (Jab/CSN5) induces cytoplasmic 
localization and degradation of RUNX3 [155]. In addition, histone methyltransferase G9a has 
also been shown to promote nuclear export and induce degradation of RUNX3 in response to 
hypoxia [156]. Similarly, CagA might promote nuclear export of RUNX3 by sequestering 
RUNX3 in the cytoplasm where it can be ubiquitinated and degraded by the 26S proteasome.  
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Aberrant DNA methylation of CpG islands of promoters is one of the major mechanisms 
for inactivating tumor suppressor genes and is closely involved in the formation of cancer [157]. 
Not surprisingly, methylation of Runx3 promoter represents a major mechanism for the 
inactivation of RUNX3 in gastric cancer. Hypermethylation of Runx3 promoter is found in many 
gastric cancer cell lines and gastric cancer samples as well as in the non-cancerous gastric 
diseases including chronic gastritis, intestinal metaplasia and gastric adenoma with less 
frequency than cancer [157, 158]. Several factors including H. pylori infection, inflammation, 
and oxidative stress have been indicated to be involved in the epigenetic inactivation of RUNX3 
[159]. H. pylori infection positively correlates with the methylation of Runx3 promoter in gastric 
cancer as well as with gastric atrophy and intestinal metaplasia [110]. Supporting the role of H. 
pylori infection in the methylation of Runx3 promoter, eradication of H. pylori increases the 
expression of RUNX3 in the glandular epithelial cells of the corpus [160]. 
 
It is well documented that RUNX3 functions as a tumor suppressor under the TGF- 
signaling pathway through attenuation of cell growth and induction of apoptosis [161].  For 
example, RUNX3 suppresses gastric epithelial cell growth by inducing cell cycle regulator 
p21
(WAF1/Cip1)
 expression and induces apoptosis of gastric epithelial cells by up-regulating pro-
apoptotic factor Bim [55, 56]. Therefore, inactivation of RUNX3 by H. pylori might result in 
enhanced gastric epithelial cell proliferation and survival, which in turn facilitates H. pylori 
colonization [162]. Additionally, inactivation of RUNX3 by H. pylori might contribute to 
disruption of the proper architecture of the gastric epithelium. Claudin-1, a main component of 
the tight junction family proteins, is a direct and positive target of RUNX3 in gastric epithelial 
cells. Runx3
-/- 
derived gastric epithelial cells have reduced levels of claudin-1 and increased 
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tumorigenic potential when compared with Runx3
+/+
 cells [57]. Disruption of the tight junction 
might allow H. pylori to invade intercellularly and further induce cell motility, elongation and 
result in onset of mitotic genes involved in cell proliferation.  
 
In the first part of this conclusion, I summarize the recent findings that define the 
important role of H. pylori in the inactivation of gastric tumor suppressor RUNX3. Multiple lines 
of evidence demonstrate that various pathways and factors are involved in H. pylori-mediated 
inactivation of RUNX3. While the degradation of RUNX3 might represent one of the primary 
responses to host-pathogen interaction, providing a rapid outcome for proliferation and survival 
of gastric epithelial cells and the growth of H. pylori, the infection-mediated long-term silencing 
of RUNX3 at the epigenetic level might allow transdifferentiation of gastric epithelial cells to 
intestinal-type cells. H. pylori infection is a major risk factor for the development of gastric 
cancer and its precursor lesion [73] and H. pylori eradication with triple therapy has been an 
effective approach for prevention of gastric cancer [163, 164]. However, due to increased 
antibiotic-resistance and some beneficial effects from H. pylori infection, alternative medical 
approaches for H. pylori infection are required to be considered [165]. However, such new 
approaches rely on a better understanding of the molecular and cellular mechanism for H. pylori-
induced gastric cancer. Although detailed mechanisms for the H. pylori-mediated inactivation of 
RUNX3 remain to be determined, this line of research promises to yield new insights into the 
pathogenesis of H. pylori and gastric cancer. Since inactivation of RUNX3 is closely associated 
with pathogenesis of H. pylori, specifically blocking the interaction between H. pylori CagA and 
RUNX3 in H. pylori-infected patients or reactivation of RUNX3 in gastric lesions and gastric 
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cancers by reducing methylation of Runx3 promoter might reduce the tumorigenic potential of H. 
pylori but at the same time retain its beneficial effect.  
 
In the second part of my thesis, I will discuss the regulation of RUNX3 in breast 
carcinogenesis. The role of RUNX3 as a tumor suppressor in breast cancer has been less 
extensively studied compared to its role in gastric cancer. However, our lab has clearly defined 





spontaneously developed ductal carcinoma at an average of 14.5 months due to 
hyperproliferation of mammary ductal epithelial cells. Additionally, RUNX3 also inhibits the 
estrogen-dependent proliferation and transformation potential of ER-positive MCF-7 breast 
cancer cells in liquid culture and in soft agar and suppresses the tumorigenicity of MCF-7 cells in 
severe combined immunodeficiency (SCID) mice [33].  
 
Breast carcinoma is the most prevalent form of cancer amongst women in developed 
countries such as the United States (US). From 2001 to 2005, the incidence rate of breast cancer 
in the US population was approximately 125 cases per 100,000 people, and the mortality rate 
was approximately 25 cases per 100,000 people, making breast cancer death rates the second 
highest of all cancers after lung cancer [86]. Excluding cancers of the skin, breast cancer is the 
most frequently diagnosed form of cancer among women in the US, making up more than 1 in 
every 4 cancers diagnosed. Women in the US have a 1 in 8 chance of developing breast cancer in 
their lifetime. Women between 75 and 79 years of age have the highest risk of developing cancer, 
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with an incidence rate of 464.8 cases per 100,000 as compared to an incidence rate of 1.4 among 
women aged between 20 and 24 years [166].  
 
Between 5 to 10% of breast cancers are thought to be hereditary, highlighting the 
importance of genetic factors in breast carcinogenesis [166]. Abnormalities in proto-oncogenes 
BRCA1 and 2 are thought to account for around 10% of breast cancers  [87]. Other common 
genetic mutations include aberrations in DNA repair gene ATM, tumor suppressor gene p53, and 
PTEN, a protein phosphatase involved in many signaling pathways including the AKT signaling 
pathway. Up-regulation of Pin1, a peptidy-prolyl cis-trans isomerase (PPIase), is also believed to 
be genetically linked to breast oncology. Pin1 is known to play a role in multiple oncogenic 
signaling pathways, and Pin1 over-expression in breast cancer is also associated with poor 
prognosis of the breast cancer patients [116, 133].   
 
PPIase Pin1 is composed of an N-terminal protein-protein interaction WW domain, and a 
C-terminal PPIase domain. The WW domain of Pin1 preferentially binds to peptides containing a 
phosphorylated serine or threonine residue preceding a proline residue (pS/T-P) motif, while the 
PPIase domain catalyzes cis-trans isomerization of the peptide bond on the amino-terminal side 
of the proline residue [116]. Through associations with its substrates, Pin1 has been found to 
affect phosphorylation status, protein-protein interactions, subcellular localization and protein 
stability [116, 121, 123, 133]. In the third chapter of my thesis, I report that RUNX3, a tumor 
suppressor in breast cancer, is found to be a new substrate of Pin1 and is inactivated by Pin1. We 
observed a significant inverse correlation between the expression of RUNX3 and Pin1 in human 
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breast cancer specimens as well as breast cancer cell lines. Inhibition of Pin1 up-regulates 
RUNX3 expression in a breast cancer cell line and Pin1 is also found to inhibit the 
transcriptional activity of RUNX3. Through further analysis of the two proteins, we found that 
Pin1 binds to RUNX3 in a method common to its interactions with its other substrates: through 
its WW domain binding pocket in the N-terminus. What is most intriguing is that RUNX3 has 
four distinct S/T-P motifs that interact with Pin1, it is only upon mutations of all four motifs that 
RUNX3 and Pin1 interaction is abolished, which prompted us to wonder if each of these four 
Pin1 binding sites corresponds to the disruption of distinct target functions of RUNX3?  Detailed 
characterization of the Pin1 binding sites on RUNX3 will provide further insights into the 
inactivation of RUNX3 by Pin1.  
 
We also found that Pin1 induced the ubiquitination of RUNX3 and subsequently target 
RUNX3 for proteasome degradation. Pin1 is known to control the degree of ubiquitination of its 
substrates and altering the fate of these proteins in cells [167]. For example, Pin1 is able to 
switch tumor suppressor, p53, from poly-ubiquitination, which triggers nuclear p53 degradation 
to oligo-ubiquitination, which triggers the nuclear export of p53 [168]. Pin1 has also been found 
to induce poly-ubiquitination of Smad2/3 proteins in the TGF-β signaling pathway by 
recruitment of E3 ligase Smurf2, and targeting Smad2/3 for proteasome degradation [134].  
Moreover, RUNX3 is known to be ubiquitinated by Smurf 2 E3 ligase [58]. This, together with 
RUNX3’s well documented involvement in the TGF-β signaling pathway suggest that perhaps 
the E3 ligase that mediate Pin1-induced RUNX3 ubiquitination might also be Smurf2 or a 
member of the Smurf E3 ligase family. Identification of the E3 ligase involved in the inactivation 
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of RUNX3 by Pin1 will provide more potential therapeutic targets in the treatment of breast 
carcinogenesis.  
 
Pin1 is known to be involved in breast development and oncogenesis through a number 
of pathways, including activation of oncogenic HER/Neu/Erb2 and Ras signaling pathway, 
leading the enhancement of cyclin D1 gene via transcription factors like E2F, c-Jun.AP-1 and β-
catenin/TCF [169-173]. Through the identification of inactivation of RUNX3 by Pin1, we gain 
further understanding of Pin1’s role in breast carcinogenesis.  
 
Mechanisms underlying the inactivation of RUNX3 in breast cancer are largely unknown.  
Approximately 80% of breast cancer specimen is known to inactivate RUNX3 through 
cytoplasmic sequestration of RUNX3 [34]. Nuclear exclusion of RUNX3 can occur through a 
number of methods, including microtubule-dependent nuclear import, reducing nuclear retention 
by loss of association with chromatin-related macromolecular complexes and inhibiting nuclear 
import [174, 175]. TGF-β signaling pathway is also thought to trigger nuclear import of RUNX3 
in certain cell types [82], but due to the pathway being impaired in many breast cancer cells, this 
could be the reason why RUNX3 is mis-localized to the cytoplasm in breast cancer. However, it 
is unknown how TGF-β elicits nuclear translocation of RUNX3, or what kind of perturbations 
happen in cells to induce nuclear exclusion or inhibit nuclear import of RUNX3. RUNX3 is also 
functionally inactivated in breast cancer through hypermethylation of the Runx3 promoter [34]. 
However, like cytoplasmic mis-localization, it is still largely unclear what causes the aberrant 
methylation of RUNX3. Identification of Pin1-induced RUNX3 degradation helps us establish 
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one of the mechanisms behind RUNX3’s functional inactivation, perhaps one of the initial 
responses in the mammary carcinogenesis process. Perhaps like gastric cancer, with the 
inactivation of RUNX3 by Pin1 in mammary tissues, it provides an initial prompt for cell 
proliferation and transformation leading to oncogenesis. With a known mechanism, it will aid in 
the discovery of therapeutic targets for breast cancer.  
 
RUNX3’s anti-tumor activities in breast cancer are also unclear. Huang et al. in our lab 
recently identified RUNX3 mediation of ERα degradation as an anti-tumor mechanism of 
RUNX3 in ERα breast cancer [33]. ER functions as a transcriptional regulator, stimulating 
proliferation and suppressing apoptosis through regulation of genes involved in the cell cycle and 
apoptosis. Abnormal estrogen signaling through ER is associated with initiation and 
progression of breast cancer [91]. In ERα positive cells, RUNX3 controls the cellular amount of 
ERα and function as gatekeeper [33], preventing the onset of breast cancer. However, in ER-
negative MDA-MB-231 cells, RUNX3 was also found to reduce the invasiveness and tumor 
formation potential of these cells [34], indicating that RUNX3 also has tumor suppressor 
functions in ERα negative cancers. In these cancers, it is possible that RUNX3 functions under 
the TGF-β signaling pathway like in gastric cancer. RUNX3 may cooperate with FOXO3a or 
receptor-regulated Smads to induce TGF-β mediated cell cycle arrest or apoptosis. In general, 
further understanding is needed with regards to the tumor suppressor function of RUNX3 in 




In conclusion, multiple lines of evidence points towards RUNX’s close link to cancer 
pathogenesis. Frequent inactivation of RUNX3 as well as the interaction of RUNX3 with 
important components of various signaling pathways, for example enhancement of TGF-β-
related growth inhibition and apoptosis as well as suppression of oncogenic Wnt signaling 
activity clearly indicate that aberrant activity of RUNX3 plays a major part in oncogenesis. 
Furthermore, with the increase list of proteins that has been identified to interact with RUNX3 
hints at the involvement of RUNX3 in other activities such as DNA damage and repair. 
Therefore, a more complete understanding of RUNX3’s regulation and inactivation mechanisms 
in respective tissues will offer important insights into the complicated steps of cancer formation, 
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